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Osteoporosis (OP) is a disease of progressive bone loss that is intimately linked with 
bone remodeling, a lifelong process of turnover essential for the maintenance of bone 
microarchitecture. Remodeling involves processes of coupled bone resorption and formation, 
carried out by complex cellular groupings known as basic multicellular units (BMUs). 
Imbalances in remodeling, where bone resorption exceeds formation, leads to elevations in 
cortical porosity and an increased risk of OP. Understanding the spatio-temporal coordination of 
BMUs is the key to elucidating the mechanisms underpinning cortical bone loss associated with 
OP and developing therapeutic approaches aimed at improving the balance between BMU phases 
to minimize bone loss. Much of the research on this subject has been largely theoretical or in 
silico thus far due to the lack of direct empirical evidence. Combining the use of high-resolution 
synchrotron based micro-computed tomography (micro-CT), a powerful imaging tool capable of 
characterizing cortical porosity in three-dimensional (3D) space, with the appropriate animal 
model has the potential to directly track individual BMUs and assess their behaviours in vivo. 
Rabbits are suitable model systems since they are the smallest laboratory animals to exhibit 
cortical bone remodeling like humans, however, remodeling rates in their cortices are generally 
low and approaches aimed at increasing remodeling have largely focused on trabecular bone. 
Therefore, there exists a need to develop an operationally effective cortical bone model given the 
growing recognition of the role cortical bone microarchitecture plays in bone loss and fragility in 
OP. The primary aim of this thesis was to establish a cortical porosity model in the rabbit using 
parathyroid hormone (PTH), a known inducer of cortical remodeling at intermittent levels. The 
experiment described in this thesis is presented as one aspect of a larger study characterizing 
numerous rabbit-based models of cortical bone loss (ovariectomy and glucocorticoid induced), 
all of which are compared to a control. After one month of intermittent PTH administration, 
cortical bone microarchitectural changes in the distal tibiae of rabbits were assessed ex vivo using 
micro-CT at a resolution of 10 µm and dynamic histomorphometry. Trabecular bone 
microarchitecture of the proximal tibial epiphysis was assessed secondarily. Results indicated 
that cortical porosity was substantially elevated in PTH rabbits relative to controls, and this was 
associated with increases in remodeling rate and cortical pore size. Despite bone losses 
intracortically, bone formation was evident on endosteal and periosteal surfaces of the tibiae and 
the rate of new bone deposition was increased in BMUs. Furthermore, a pattern of bone gain was 
observed in the proximal tibial epiphysis indicated by changes in micro-CT derived trabecular 
microarchitectural parameters. Notably, remodeling induced by PTH appeared to be distinct 
from that of the other rabbit-based models of bone loss in this larger study, with regards to 
cortical porosity and trabecular bone structural changes, warranting further investigations into 
these intriguing PTH-driven effects. Overall, the PTH rabbit model provides an effective and 
novel platform for developing future mechanistic studies aimed at testing a number of 
hypotheses directly related to bone remodeling regulation, which would ultimately enhance our 




I would like to express my deepest gratitude to my supervisor Dr. Dave Cooper for his 
endless support, guidance, and assistance during this journey. He has been such an important part 
of my academic and personal development, helping me foster my interest in the scientific 
process and providing me with an abundance of knowledge and invaluable advice that I will be 
taking with me into the next chapter of my life. I also greatly appreciate the many additional 
opportunities Dave has provided me with that have enriched my research program, like working 
on other projects, attending conferences, and gaining teaching experience. Dave exemplifies 
everything a researcher, supervisor, and mentor should be and I feel so privileged to have 
worked with someone who is so hard working and dedicated to his students and work.  
I would like to extend my gratitude to the other members of my advisory committee, Drs. 
Julia Boughner and Terra Arnason. I am grateful for their insights and thoughtful inputs on my 
work and appreciative of their helpful advice, both in and outside of the lab. 
I would especially like to thank the co-authors of the manuscript included in this thesis 
for their contributions: Kim Harrison, Arash Panahifar, Janna Andronowski, Amir Ashique, 
Gavin King, Terra Arnason, Kurtis Swekla, Peter Pivonka, and of course, Dave. I would like to 
further thank my co-lead author Kim, for making this partnership such an easy and enjoyable one 
(despite the many late nights of work!) and for being such a great friend to me. I would also like 
to thank the Laboratory Animal Services Unit for their assistance with the rabbits, Ingrid 
Pickering and Natalia Dolgova for training and use of the confocal microscope, and Adi Manek 
for generously lending his expertise, time, and efforts with optimizing the histology work. 
I would like to recognize the various sources of funding that have made this research 
possible – the Canadian Institutes of Health Research, the University of Saskatchewan College of 
Medicine, and to Dave Cooper, for his generosity and support.  
My sincerest thanks go out to my fellow Cooper lab mates, past & present, for not only 
providing me with scientific and emotional support but also for the indispensable friendships and 
laughs. I would particularly like to thank Kim Harrison, Gavin King, and Kush Parolia for the 
countless office conversations and puzzle breaks that have kept me sane during this journey.  
I would like to acknowledge my first grad school friends, Lexi Busse and Cassy Appelt, 
whom I surely would not have been able to endure the ups and downs of grad school without.  
I am grateful for my long distance support systems; to Ally Simms and Nicole Breedon 
for their friendships and positive words of encouragement and to my second family, Manda 
Guest, Scott Van Os, Aurora-Lyn, and Ezmay, for their undeniable support and for always being 
there for me throughout my academic pursuits.   
Last but certainly not least, I would like to sincerely thank my family – to my parents for 
their unconditional love and support (emotionally & financially), to Amanda and Derek (and 
pups!) for always having my back no matter what, and to my twin/roommate/best friend Crystal, 
who deserves the greatest recognition for being my rock throughout this whole journey. I can 
honestly say that this achievement would not have been possible without her unwavering 











I dedicate this thesis to my dad, mom, and sisters. 





































TABLE OF CONTENTS  
 
PERMISSION TO USE ................................................................................................................. i 
ABSTRACT ................................................................................................................................... ii 
ACKNOWLEDGEMENTS ........................................................................................................ iii 
DEDICATION ............................................................................................................................. iv 
TABLE OF CONTENTS ............................................................................................................. v 
LIST OF TABLES ...................................................................................................................... vii 
LIST OF FIGURES ................................................................................................................... viii 
LIST OF ABBREVIATIONS ................................................................................................... xiv 
CHAPTER 1. Introduction .......................................................................................................... 1 
1.1. Introduction .................................................................................................................. 1 
1.11. Bone Microarchitecture & Remodeling ......................................................... 1 
1.12. Osteoporosis ................................................................................................... 5 
1.13. Analysis of the Dynamic Activity of BMUs with Histology and Imaging .... 6 
1.14. Animal Models of Cortical Bone Turnover ................................................... 8 
1.2. Thesis Objectives ......................................................................................................... 9 
1.3. Organization of Thesis ................................................................................................. 9 
CHAPTER 2. Parathyroid Hormone Effects on Bone ............................................................ 11 
2.1. Introduction ................................................................................................................ 11 
2.2. Intermittent PTH ........................................................................................................ 11 
2.21. Intermittent PTH Effects in Trabecular Bone .............................................. 12 
2.22. Intermittent PTH Effects on Endosteal and Periosteal Surfaces .................. 14 
2.23. Anabolic Effects & Timing .......................................................................... 15 
2.24. Cellular Mechanisms of Bone Apposition ................................................... 16 
2.25. Intermittent PTH Effects on Intracortical Bone ........................................... 17 
2.3. Continuous PTH Effects on Cortical and Trabecular Bone ....................................... 18 
2.4. PTH Effects on Rabbit Bone ...................................................................................... 20 
2.5. Conclusion ................................................................................................................. 21 
CHAPTER 3. Cortical Bone Porosity in Rabbit Models of Osteoporosis ............................. 22 
3.1. Introduction ................................................................................................................ 22 
3.2. Materials and Methods ............................................................................................... 24 
3.21. Animals ........................................................................................................ 24 
3.22. Micro-CT Analysis ....................................................................................... 25 
3.23. Dynamic Histomorphometry & Cortical Geometry ..................................... 27 
3.24. Statistical Analysis ....................................................................................... 28 
	 vi 
3.3. Results ........................................................................................................................ 28 
3.31. Animal Weight ............................................................................................. 28 
3.32. Cortical Porosity ........................................................................................... 31 
3.33. Cortical Bone Geometry ............................................................................... 36 
3.34. Cortical Bone Histomorphometry ................................................................ 39 
3.35. Trabecular Bone Micro-CT .......................................................................... 43 
3.4. Discussion .................................................................................................................. 46 
3.5. Conclusion ................................................................................................................. 51 
3.6. Supplementary Materials ........................................................................................... 52 
CHAPTER 4. Conclusion ........................................................................................................... 58 
4.1. Thesis Overview ........................................................................................................ 58 
4.2. Future Directions ........................................................................................................ 60 
REFERENCES ............................................................................................................................ 65 
APPENDIX A .............................................................................................................................. 80 
A.1. Methylmethacrylate Embedding for Undecalcified Bone ......................................... 80 
A.2. Serial Sectioning of Undecalcified Bone with Automated Microtome .................... 83 
A.3. Optical Sectioning of Bone with Confocal Microscope ........................................... 85 

















LIST OF TABLES          
  
Table 3.1. Rabbit Weight Analyses .............................................................................................. 30	
Table 3.2. Micro-CT Cortical Bone Parameters .......................................................................... 34	
Table 3.3. Cortical Bone Geometry Parameters ........................................................................... 38	
Table 3.4. Cortical Bone Histomorphometric Parameters ........................................................... 42	






























LIST OF FIGURES 
 
Figure 1.1.  Micro-CT image depicting cortical and trabecular bone. This scan was taken from 
the proximal epiphysis of the tibia from a rabbit. Cortical bone comprises the outer 
shell surrounding trabecular bone and the inner marrow cavity. .............................. 1 
	
Figure 1.2.  Schematic of a transverse section through a long bone undergoing bone modeling. 
The independent actions of osteoclasts and osteoblasts modify the external structure 
of bone, in this case, removing bone from the endosteal surface and adding bone to 
the periosteal surface, contributing to the bone’s appositional growth or as an 
adaptation to mechanical loads. ................................................................................. 2 
	
Figure 1.3.  Schematic illustrating cortical and trabecular bone remodeling. In cortical bone, 
osteoclasts remove old or damaged bone creating a tunnel like resorption space 
known as the cutting cone. Osteoblasts follow in the closing cone, filling the space 
with new bone, first as osteoid, then as mineralized bone. A reversal zone exists 
between the two phases, coupling bone resorption to bone formation. Collectively, 
this group of cells is known as a basic multicellular unit (BMU) and their activity 
creates a new secondary osteon. Trabecular bone remodeling results in a BMU of 
different morphology than that of cortical bone. Osteoclasts resorb bone on a 
surface to form a trench, which is then refilled by new bone via osteoblasts, 
creating a hemi-osteon. .............................................................................................. 4 
	
Figure 1.4.  Micrograph of a secondary osteon in cortical bone (transverse section, 20X). The 
secondary osteon is a product of bone remodeling consisting of layers of bone 
(lamellae) surrounding the central canal, which contains the neurovascular bundle 
that sustains the osteocytes, or bone cells. The lamellae are enclosed within the 
outer boundary of the osteon, known as the cement line. Secondary osteons can be 
distinguished from primary osteons, the vascular canals found in primary bone 
created during growth, by their larger size and more abundant lamellae. ................. 5 
	
Figure 1.5.  A schematic of a longitudinal section of cortical bone depicting a BMU analyzed 
with dynamic histomorphometry. Dual bone fluorochrome labels, which 
incorporate into newly mineralized bone, are administered in vivo to enable the 
direct quantification of closing cone advance, or the amount of bone formed within 
the labelling period (distance between 1nd Label and 2nd Label). Longitudinal 
erosion rate (LER), or the rate of cutting cone advance (distance between Time 1 
and Time 2), has only been inferred from the rate of closing cone advance, under 
the assumption that the two activities are equal. This histological measure of LER 
was measured in two classic studies from the 1970s (28, 29). .................................. 7 
	
	 ix 
Figure 2.1.  Confocal micrograph of a histological transverse section of cortical bone depicting 
fluorescent bone labels (green). Primary histomorphometric measures of bone 
formation activity can be quantified from these fluorochrome labels that appear on 
periosteal and endosteal surfaces and in intracortical BMUs. They can also be 
measured on trabecular bone surfaces. Mineralizing surface per bone surface 
(MS/BS) is measured as the full extent of double labelled bone surfaces plus half 
the extent of single labelled bone surfaces, normalized to the total bone surface. 
Mineral apposition rate (MAR) can be measured from double labelled surfaces as 
the distance between two fluorochrome labels divided by the time between label 
administrations. Bone formation rate (BFR) can then be calculated as the product of 
these two parameters. .............................................................................................. 13 
	
Figure 3.1.  Micro-Computed Tomography (micro-CT) image of rabbit tibia depicting regions 
of analyses. (A) Location of trabecular bone micro-CT analysis. Scan field height is 
1 cm. Reconstructed micro-CT image of proximal tibia scan and corresponding 
three-dimensional reconstructed image of isolated trabecular bone highlighted in 
yellow (right). (B) Location of histomorphometric analysis. Section is 300 µm 
thick. Fluorescent confocal microscopy image of transverse section of cortical bone 
(right). (C) Location of cortical bone micro-CT analysis. Scan field height is 1 cm. 
Three-dimensional reconstructed image of cortical bone with cortical porosity 
highlighted in yellow (right). ................................................................................... 26 
	
Figure 3.2.  Analyses of mean changes in body weight in rabbit groups over experimental time 
period (0-3 months). Data are presented by boxplots with individual rabbits plotted 
as solid circles and outliers plotted as open circles. N=7. *Indicates p < 0.05 
compared to 0 (independent sample t test). SHAM = control. OVX = Ovariectomy. 
GC = Glucocorticoid. OVX+GC = Ovariectomy & Glucocorticoid. PTH = 
Parathyroid Hormone. ............................................................................................. 29 
	
Figure 3.3.  Micro-CT based analyses of cortical bone in rabbit tibiae. (A) Representative two-
dimensional micro-CT cross sectional images of cortical bone in distal rabbit tibiae 
in various treatment groups with corresponding three-dimensional renders of 
volume of interest (below). Regions of cortical porosity at the level of vascular 
canals are highlighted in yellow. Scale bar = 1 mm. (B) Cortical Porosity (Ct.Po) 
analysis in rabbit tibiae. Data are presented by boxplot with individual rabbits 
plotted as solid circles and outliers plotted as open circles. N=7. *Indicates p < 
0.0125 compared to SHAM (Kruskal-Wallis with post-hoc Dunn’s test). (C) Canal 
Diameter (Ca.Dm) analysis in rabbit tibiae. Data are presented by boxplot with 
individual rabbits plotted as solid circles and outliers plotted as open circles. N=7. 
*Indicates p < 0.0125 compared to SHAM (One-way ANOVA with post-hoc 
Bonferroni test). (D) Histograms depicting distributions of canal diameters in rabbit 
	 x 
tibiae for each group. SHAM = control. OVX = Ovariectomy. GC= Glucocorticoid. 
OVX+GC = Ovariectomy & Glucocorticoid. PTH = Parathyroid Hormone. ......... 32 
	
Figure 3.4.  (A) Differential Interference Contrast (DIC) and fluorescent confocal microscopy 
images of transverse sections of rabbit tibiae in various treatment groups. Green 
fluorescent signal from calcein depicts areas of active bone formation. Absent 
signals from GC treated rabbits are due to inhibition of osteoblastic mediated bone 
formation by GC treatment. Scale bar = 1 mm. SHAM = control. OVX = 
Ovariectomy. GC = Glucocorticoid. OVX+GC = Ovariectomy & Glucocorticoid. 
PTH = Parathyroid Hormone. (B-D) Representative confocal microscopy images of 
(B) single labelled osteon, (C) double labelled osteon, and (D) resorption cavity. 
Scale bar = 50 µm. (E) Confocal microscopy image of PTH endosteal surface in 
transverse section. Note the trabecularized appearance of bone formed on the 
endosteal surface, a feature typical of woven bone. Scale bar = 150 µm. (F) 
Corresponding three-dimensional reconstructed micro-CT image of PTH endosteal 
surface. (G) Confocal microscopy image of GC endosteal surface in transverse 
section. Note scalloped appearance of endosteal bone. Scale bar = 150 µm. (H) 
Corresponding three-dimensional reconstructed micro-CT image of GC endosteal 
surface. ..................................................................................................................... 35 
	
Figure 3.5.  (A-I) Cortical bone geometry analyses in rabbit tibiae. Data are presented by 
boxplots with individual rabbits plotted as solid circles and outliers plotted as open 
circles. N=7. *Indicates p < 0.0125 compared with SHAM (One-way ANOVA with 
post-hoc Bonferroni test). Ct.Ar = Cortical Area. Ma.Ar = Marrow Area. Tt.Ar = 
Total Area. Ct.Th = Cortical Thickness. Imax = Maximum second moment of area. 
Imin = Minimum second moment of area. Zpol = torsional section modulus. SHAM = 
control. OVX = Ovariectomy. GC = Glucocorticoid. OVX+GC = Ovariectomy & 
Glucocorticoid. PTH = Parathyroid Hormone. ........................................................ 37 
	
Figure 3.6.  (A-J) Histomorphometric analyses of transverse cortical bone sections in rabbit 
tibiae. Data are presented by boxplots with individual rabbits plotted as solid circles 
and outliers plotted as open circles. N=7 except for On.MAR and Ac.f measures for 
OVX (N=5) and SHAM (N=3). *Indicates p < 0.0125 compared to SHAM unless 
otherwise stated (Kruskal-Wallis with post-hoc Dunn’s test for dL.On/Ct.Ar, 
sL.On/Ct.Ar, Rs.N/Ct.Ar, a.Rm.Cr/Ct.Ar, and W.Th). For On.MAR, Ac.f, 
PS.MS/BS, and Es.MS/BS, *indicates p < 0.025 (One-way ANOVA with post hoc 
Bonferroni test for Es.MS/BS, On.MAR, and Ac.f, Kruskal-Wallis with post-hoc 
Dunn’s test for PS.MS/BS). sL.On = Single Labelled Osteon. dL.On = Double 
Labelled Osteon. Rs.N = Resorption Cavity Number. a.Rm.Cr = Active 
Remodeling Centers. Ct.Ar = Cortical Area. W.Th = Wall Thickness. On.MAR = 
Osteonal Mineral Apposition Rate. Ac.f = Activation Frequency. Es = Endosteal. 
	 xi 
Ps = Periosteal. MS/BS = Mineralizing Surface per Bone Surface. SHAM = control. 
OVX = Ovariectomy. GC = Glucocorticoid. OVX+GC = Ovariectomy & 
Glucocorticoid. PTH = Parathyroid Hormone. ........................................................ 41 
	
Figure 3.7.  Micro-CT based analyses of trabecular bone in rabbit tibiae. (A) Three-dimensional 
reconstructed images of epiphyseal subchondral trabecular bone structure in rabbit 
tibiae of various treatment groups. Regions of trabecular bone are highlighted in 
yellow. Scale bar = 1 mm. (B-E) Three-dimensional trabecular bone analyses in 
rabbit tibiae. Data are presented by boxplots with individual rabbits plotted as solid 
circles and individual outliers plotted as open circles. N=7. *Indicates p < 0.0125 
compared to SHAM (One-Way ANOVA with post-hoc Bonferroni test for Tb.Th 
and BV/TV, Kruskal-Wallis with post-hoc Dunn’s test for Tb.Sp and Tb.N). 
BV/TV = Bone Volume/Tissue Volume. Tb.Th = Trabecular Thickness. Tb.N = 
Trabecular Number. Tb.Sp = Trabecular Separation. SHAM = control. OVX = 
Ovariectomy. GC = Glucocorticoid. OVX+GC = Ovariectomy & Glucocorticoid. 
PTH = Parathyroid Hormone. .................................................................................. 44 
	
Figure 3.81. Micro-CT Canal Diameter Resolution Dependency. A block of distal tibial cortical 
bone (1.5 mm x 3.0 mm) from a PTH animal was imaged at 2, 4, 6, 8, and 10 µm 
voxel using the instrument and protocols described in the materials and methods. 
3D renders of a matching volume of interest from the highest (2 µm; A) and lowest 
resolutions (10 µm; B) are depicted. The size of the bounding boxes around the 
render is approximately 950 x 1300 x 2250 µm. Below, % volume distributions of 
canal diameter (Ca.Dm) (comparable to Figure 3D) are plotted for all resolutions 
(C) and for just the highest and lowest resolutions with the former histogram data 
rescaled to match the latter (D). At 2 µm, there is intermittent detection of osteocyte 
lacunae as well as detection of quiescent primary and secondary canals whereas at 
10 µm only the largest of pores, corresponding to active or recently active 
remodeling centers, were resolved. The pore size distributions quantitatively reflect 
what was visible in the 3D renders.  As resolution was reduced, there was a loss of 
smaller pores and thus larger pores increasingly dominated the % volume 
distributions. Since the higher resolutions have smaller histogram bins (C) the 
contributions of each of these is relatively smaller, explaining the upward trend in 
percentages evident. When the histogram bin sizes were rescaled (C) it was clearly 
apparent that the higher resolution had a larger % contribution of smaller canals 
than the lower resolution scan. Notably, however, both distributions had a peak at 
the expected (~100 µm) size of normal rabbit secondary osteon diameter. Our 
analysis proceeded with the 10 µm voxel size as it afforded good characterization of 
remodeling-related pores, maximized field of view, minimized data size and, 
ultimately, exceeded resolutions previously employed to characterize cortical 
porosity in rabbit bone by micro-CT (see materials and methods). ........................ 52 
	 xii 
	
Figure 3.82. Validation of Micro-CT Assessment of Canal Diameter. To validate 3D micro-CT 
based measurements of Ca.Dm, the size (Feret’s diameter) of up to 20 resorption 
cavities from each animal was assessed manually in 2D from the confocal DIC 
images using ImageJ. Matching the analysis presented in the manuscript, mean 2D 
Ca.Dm was assessed by ANOVA with pairwise post-hoc tests against SHAM. As 
depicted in A, 2D Ca.Dm was greater than SHAM for GC, OVX+GC, and PTH – 
an overall result very similar to that of 3D Ca.Dm with the exceptions that GC was 
significant in 2D and not 3D and PTH was significant in 3D but not 2D. Bland-
Altman plots revealed a significant but expected bias between the approaches with 
the 3D micro-CT measure generating lower values (22.0, one sample t test vs. 0, p 
< 0.001) due to the inclusion of canals ranging from the maximum diameter of 
cutting-cones down to the limits of the 10 µm nominal resolution (see Supplemental 
Figure 1). While different, the two approaches produced significantly correlated 
results (r = 0.474, p < 0.005 overall; r = 0.668, p < 0.001 with the exclusion of the 
outlier evident in B; Pearson’s, p < 0.01). Superimposed distributions of Ca.Dm 
from the experimental groups (C) were strikingly similar to the 3D equivalent 
shown in Figure 3 D. Superimposed distribution plots for the individual groups (D-
H) clearly demonstrate the similarity of the two techniques with the 3D measure 
having a larger % volume contribution of smaller canal diameters. As noted for the 
3D analysis in the manuscript, peaks at the expected size of 100 µm size of normal 
rabbit secondary osteons were observed in all groups except for those dosed with 
GC. These had distributions skewed towards larger canal diameters. Given the 
similarity between these approaches, despite fundamental differences in what they 
specifically measure, we have confidence in the validity of the 3D outcomes. ...... 54 
	
Figure 3.83. Variation in Cortical Porosity Within the Tibial Diaphysis. We explored variation 
in cortical porosity along the tibial diaphysis in order to select the optimal site for 
analysis, balancing the goals of suitability for future in vivo imaging and 
maximizing the detection of porosity/remodeling. Left tibiae (contra-lateral to those 
analyzed in the manuscript) from two animals from each of our experimental 
groups were imaged along their entire diaphyseal lengths using the 10 µm 
resolution and protocol previously described in the materials and methods. The 
tibiae had to be bisected in order to fit into the scanner. The presented results 
recombine the data with the caveat that some minimal data were lost at the location 
of the cut, which was placed just distal to the tibio-fibular junction. Mean percent 
cortical porosity (Ct.Po, %) for the two animals from each group was plotted 
relative to the position along the diaphysis starting at 1 cm from distal tibial 
plafond. A 200-slice (2 mm) rolling average was utilized to reduce noise and better 
facilitate comparisons across groups. Representative 2D cross-sectional images 
along the diaphysis are presented for context (A-C; scale bar = 1 mm). The pattern 
	 xiii 
was similar across groups despite variation in the overall level of Ct.Po. Porosity 
was lowest in the mid-diaphysis and increased proximally and distally. At the point 
of the tibio-fibular junction Ct.Po increased markedly and continued to do so 
proximally before eventually declining towards the proximal epiphysis. 
Considering suitability for in vivo imaging, overall porosity level, and anatomical 
complexity (e.g., one vs. two bones), the distal tibia ultimately presented the best 
overall target for our analysis. The variation along and within the diaphyses was 
intriguing and warrants further analysis regarding the factors underpinning it (e.g., 
mechanical versus developmental). ......................................................................... 56 
	
Figure A.1.  (A-B) Fluorescent confocal and differential interference microscopy 2D image (z) 
stacks of a longitudinal section (~400 µm) of undecalcified PTH rabbit bone (from 
Chapter 3) depicting an example of a BMU from which LER can be measured 
from. In B, the white arrow indicates the tip of the cutting cone of the BMU and the 
red bar indicates the region where LER would be measured (between the 2 




















LIST OF ABBREVIATIONS 
 
° Degrees 
%  Percent 
2D Two-Dimensional  
3D Three-Dimensional  
4D Four-Dimensional  
α Alpha 
Ac.f  Activation Frequency 
a.Rm.Cr  Active Remodeling Center 
BFR Bone Formation Rate 
BMD  Bone Mineral Density 
BMU Basic Multicellular Unit  
BS  Bone Surface 
BV/TV  Bone Volume fraction 
C Celsius 
Ca.Dm  Canal Diameter 
Ct.Ar  Cortical Area 
Ct.Po  Cortical Porosity  
Ct.Th Cortical Thickness 
CCAC  Canadian Council on Animal Care 
CLS  Canadian Light Source 
CI  Confidence Interval 
cm  Centimeter 
CT  Computed Tomography  
DKK1 Dickkopf-1 
DIC Differential Interference Contrast microscopy 
dL.On  Double Labelled Osteon 
dLS  Double labelled Bone Surface 
DXA  Dual-Energy X-ray Absorptiometry 
Es.MS/BS  Endosteal Mineralizing Surface per Bone Surface 
EtOH  Ethanol 
FDA  American Food and Drug Administration 
g  Gram 
GC  Glucocorticoid (referring to both the class of drugs and within  
 Chapter 3, the group of rabbits treated with glucocorticoids) 
Gy  Gray 
HR-pQCT High Resolution peripheral Quantitative Computed Tomography 
IGF-1 Insulin-like Growth Factor 1 
Imax  Maximum second moment of area 
	 xv 
Imin  Minimum second moment of area 
in.Hg  inch of Mercury 
Kg  Kilogram 
kVp  Peak Kilovoltage  
LER  Longitudinal Erosion Rate 
M  Molar 
Ma.Ar  Marrow Area 
MAR  Mineral Apposition Rate 
Micro-CT  Micro-Computed Tomography  
ml  Milliliter 
mg  Milligram 
mm  Millimeter 
MMA  Methylmethacrylate 
ms  Millisecond 
MS/BS  Mineralizing Surface per bone Surface 
n  Sample size 
ND  No Data 
OCT  Optimal Cutting Temperature medium 
On.MAR  Osteonal Mineral Apposition Rate 
OP  Osteoporosis 
OPG  Osteoprotegerin 
OVX  Ovariectomy (referring to either the surgical procedure or in the case  
 of Chapter 3, the rabbit group subject to this procedure) 
OVX+GC  Ovariectomy & Glucocorticoid 
PBS  Phosphate Buffered Saline  
PHPT  Primary Hyperparathyroidism 
Ps.MS/BS  Periosteal Mineralizing Surface per Bone Surface 
PTH  Parathyroid Hormone (referring to both the drugs and within  
 Chapter 3, the group of rabbits treated with parathyroid hormone) 
RANKL  Receptor Activator of Nuclear factor Kappa-β Ligand 
ROI  Region of Interest  
Rs.N  Resorption Cavity  
Runx2  Runt-related transcription factor 2 
σf  Osteon formation time 
SCEM  Supercryoembedding medium 
SD  Standard Deviation 
SHAM  Sham control 
sL.On  Single Labelled Osteon 
sLS  Single Labelled Bone Surface 
Tb.N  Trabecular Number  
	 xvi 
Tb.Sp  Trabecular Spacing  
Tb.Th Trabecular Thickness 
TGF- β Transforming Growth Factor-β 
Tt.Ar  Total Area 
µA  Microampere  
µg  Microgram 
µm  Micron 
VOI  Volume of Interest 
vs  Versus 
Wnt  Mammalian homologue of wingless-related integration site in 
drosophila 
W.Th  Wall Thickness 














CHAPTER 1. Introduction 
 
1.1. Introduction 
1.11. Bone Microarchitecture & Remodeling 
Bone is a living, dynamic tissue that serves to provide mechanical support and protection 
to the body and plays an important role in calcium and phosphate homeostasis. Bone consists of 
the calcium-phosphate mineral hydroxyapatite and collagen fibers to provide compressive and 
tensile strength to bones, respectively. Bone is made up of two major structural types, trabecular 
and cortical bone (Figure 1.1). Trabecular (spongy, cancellous) bone consists of interconnected 
plates and rods of bone (trabeculae) predominantly found in bones like the vertebrae or in the 
ends, or epiphyses, of long bones. Cortical (compact) bone forms the dense outer shell of bones 
and is the primary component of the shaft or diaphysis of a long bone, surrounding the inner 
marrow cavity. The organization of bone is related to its functional needs. Trabecular bone 
provides structural support while minimizing added weight and is the primary site of mineral 
homeostasis due to its abundant surface area. Cortical bone’s dense and rigid structure 





Figure 1.1. Micro-CT image depicting cortical and trabecular bone. This scan was 
taken from the proximal epiphysis of the tibia from a rabbit. Cortical bone comprises 




Bones are formed during development by two distinct processes: intramembranous 
ossification, which involves the development of bone directly from primitive connective tissue, 
and endochondral ossification, where a cartilaginous template is gradually replaced by 
mineralized bone (2). The primary accumulation of bone tissue by these processes results in 
growth (3). During growth and development, the size and shape of bones are modified in a 
process known as modeling (3). This is accomplished by the coordinated actions of osteoclasts, 
which are multi-nucleated cells that remove or resorb bone, and osteoblasts, which are cells that 
are responsible for forming bone (4) (Figure 1.2). These processes occur independently of one 
another, taking place on separate, pre-existing bone surfaces. The bone formed during growth is 
known as primary bone, which can be deposited as lamellar bone or woven bone (1). Lamellar 
bone is characterized by parallel collagen fiber orientation, creating concentric layers of bone 
seen primarily within the diaphysis. Woven bone has an irregular appearance due to highly 
disorganized collagen fibers. This type of bone is associated with rapid growth and is also found 
during fracture repair or in states of high bone turnover. As primary bone is being deposited, 
vascular canals which may form into primary osteons through subsequent infilling with new 
bone (5). While prevalent during growth, a low level of modeling continues into adulthood and 
modeling can occur in response to alterations in mechanical loads, thereby modifying the 





Figure 1.2. Schematic of a transverse section through a long bone undergoing bone 
modeling. The independent actions of osteoclasts and osteoblasts modify the external 
structure of bone, in this case, removing bone from the endosteal surface and adding 
bone to the periosteal surface, contributing to the bone’s appositional growth or as an 
adaptation to mechanical loads.  
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After development ceases, the existing bone is continually turned over in a process 
known as bone remodeling (4). Remodeling maintains skeletal integrity throughout one’s 
lifetime by replacing old and damaged bone with new tissue and by mediating bone tissue level 
adaptation to mechanical demands associated with loading (6). Remodeling can occur in cortical 
bone and on trabecular, endosteal, and periosteal bone surfaces. The endosteal surface lines the 
inner surface of bone surrounding the marrow cavity while the periosteal surface refers to the 
outer surface of a bone. Bone remodeling consists of three highly coordinated, sequential stages: 
activation, resorption, and then formation, carried out by a group of specialized bone cells 
collectively known as the Basic Multicellular Unit (BMU) (4) (Figure 1.3). The BMUs in 
cortical and trabecular bone (as well as on bone surfaces) differ in the way they remove and form 
bone and therefore, their morphologies also differ. The remodeling process is activated by a 
molecular or mechanical signal that triggers the recruitment and differentiation of osteoclast 
precursors to a bone surface (7). Osteoclasts then resorb bone, forming a trench-like pit on 
trabecular, endosteal, and periosteal surfaces or a tunnel like resorption space known as the 
cutting cone in cortical bone. Once a trench or tunnel is excavated to a certain size, osteoblasts 
fill the space in with osteoid, an unmineralized bone matrix that eventually becomes calcified to 
form mature bone. On bone surfaces, this process yields a hemi-osteon (8) (Figure 1.3). In 
cortical bone, this new bone is deposited around a central canal in densely packed, concentric 
layers known as lamellae, creating the closing cone (Figure 1.3). The resulting structure is a 
secondary osteon or Haversian system (8) (Figure 1.4). The central canal contains a 
neurovascular bundle that supplies mature osteocytes or bone cells that are arranged in the 
lamellae. Perforating Volkmann’s canals run transversely connecting the osteons to each other as 
well as to the endosteal and periosteal surfaces (1). The cement line demarcates the outer border 
of the osteon and represents the maximum limits of the cutting cone that had been created during 
bone remodeling (6). In addition to the presence of a cement line, secondary osteons differ from 
primary osteons in that they are greater in size and have more abundant lamellae. Between the 
cutting and closing cones, a reversal zone exists, spatially and temporally coupling bone 
resorption to bone formation (Figure 1.3) (9). Within the reversal zone, osteoclastic activity 
transitions to osteoblastic activity as osteoclasts undergo apoptosis and osteoblast precursors 
differentiate into mature cells to synthesize new bone (7). The exact cellular and molecular 
mechanisms that mediate the coupling of resorption to formation has not yet been fully 
elucidated therefore BMU coupling remains as an important topic of much inquiry. Under 
normal conditions, the sequential activities within a BMU are balanced, such that bone 





Figure 1.3. Schematic illustrating cortical and trabecular bone remodeling. In 
cortical bone, osteoclasts remove old or damaged bone creating a tunnel like 
resorption space known as the cutting cone. Osteoblasts follow in the closing cone, 
filling the space with new bone, first as osteoid, then as mineralized bone. A reversal 
zone exists between the two phases, coupling bone resorption to bone formation. 
Collectively, this group of cells is known as a basic multicellular unit (BMU) and 
their activity creates a new secondary osteon. Trabecular bone remodeling results in 
a BMU of different morphology than that of cortical bone. Osteoclasts resorb bone 
on a surface to form a trench, which is then refilled by new bone via osteoblasts, 




Figure 1.4. Micrograph of a secondary osteon in cortical bone (transverse section, 
20X). The secondary osteon is a product of bone remodeling consisting of layers of 
bone (lamellae) surrounding the central canal, which contains the neurovascular 
bundle that sustains the osteocytes, or bone cells. The lamellae are enclosed within 
the outer boundary of the osteon, known as the cement line. Secondary osteons can 
be distinguished from primary osteons, the vascular canals found in primary bone 
created during growth, by their larger size and more abundant lamellae.  
 
1.12. Osteoporosis  
Normally, the integrity of the skeleton is maintained through balanced activities between 
osteoblasts and osteoclasts, but as humans age and in certain conditions, the bone remodeling 
rate accelerates and bone resorption outweighs bone formation resulting in bone loss and an 
increased risk of osteoporosis (OP) (10). Osteoporosis is a disease characterized by the structural 
deterioration of the skeleton and low bone mass, which increases the risk of fractures (11). 
Osteoporosis is classified by the different factors that contribute to bone loss. Primary OP is 
associated with aging and with estrogen deficiency in postmenopausal women (12). Secondary 
OP is defined as low bone mass in the presence of an underlying condition or pharmaceutical 
agents, such as chronic glucocorticoid (GC) treatment, immobility, anti-gravity scenarios, or in 
diseases like primary hyperparathyroidism (PHPT), where parathyroid hormone (PTH) is 
continually and excessively produced by the parathyroid gland, which under normal conditions, 
releases PTH in a pulsatile manner and responds to feedback inhibition (13). Osteoporosis has a 
large impact on the Canadian population currently afflicting 2 million Canadians (11) and 
costing the healthcare system $2.3 billion annually (14). In trabecular bone, remodeling 
imbalance leads to the thinning and loss of trabeculae (15) and its overall structure becomes less 
interconnected (16). Bone within this compartment is thought to be lost at a more rapid rate due 
to the higher rate of remodeling in comparison to cortical bone, lending to the conventional 
“trabeculocentric” view of bone loss in OP. Significant losses are however, observed within 
cortical bone with age (17, 18) and cortical bone is the site for which approximately 80% of all 
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fractures in old age occur in, such as the hip and distal wrist for example (19, 20). Cortical bone 
loss results from elevations in porosity as well as the size of cortical pores themselves, increasing 
the likelihood of coalescence in regions near the endosteal surface, leading to cortical thinning 
(21). Currently, therapies for treating osteoporosis are aimed at reducing bone resorption like 
widely used anti-resorptive drugs such as bisphosphonates and denosumab. These approaches 
rely on inhibiting osteoclastic formation and activity to increase bone mineral density (BMD), 
however this is a result of increased mineralization of the existing bone and not the acceleration 
of new bone formation. These treatments cannot reverse the structural deterioration that is 
already present at the time of treatment (22) and because of the coupled nature of BMU phases, 
bone formation will not ensue as bone resorption is suppressed. Furthermore, while the use of 
these treatments are generally safe and widely used, there is a growing body of literature 
documenting rare yet serious side effects of these drugs (ie., osteonecrosis of jaw, atypical 
femoral fractures, fatal strokes, and venous thromboembolic events) (23-26). Because OP arises 
from an imbalance in bone remodeling processes, strategies to prevent or reverse osteoporosis 
must aim to improve the balance between the resorptive and formative phases within individual 
BMUs. The ideal therapy for individuals susceptible to OP would involve slowing down the rate 
of resorption, both longitudinally and radially, while speeding up formation to minimize bone 
loss. Such therapies are not yet developed or available. In order to reach this potential, we need 
to have a thorough understanding of the spatio-temporal behaviour of BMUs. 
 
1.13. Analysis of the Dynamic Activity of BMUs with Histology and Imaging 
Despite its significance for bone adaptation and disease, the spatio-temporal behaviour of 
BMUs has never been replicated in vitro, nor has is been directly observed in vivo, and therefore 
there is little known about the three-dimensional (3D) or four-dimensional (4D) coordination of 
remodeling events. While we do know of factors that affect BMU activity and contribute to 
osteoporosis (certain disease states, pharmaceutical use), it is not well established how these 
factors impact the rate of advance or the coordination of remodeling events within an individual 
BMU. Elevations in porosity may be a result of an increase in the rate of BMU progression, an 
increase in the number of BMUs, or both. Most of the dynamic activity we know about BMUs is 
formative, largely derived from histological bone fluorochrome labelling studies, or dynamic 
histomorphometry, which enables the analysis of the rate of change in bone tissue, particularly 
with regards to remodeling (4, 27). Bone fluorochrome labels bind to newly calcified bone, 
thereby labelling the osteoblastic closing cone at the time of administration. The fluorescent label 
can be visualized in a histological section of a bone biopsy with ultraviolet or blue light. When 
labels are administered at two different time points, the amount of bone formed within that time 
interval, measured as the distance between the two labels, can be determined from longitudinal 
histological sections (Figure 1.5). Aspects of the resorptive phase have only been inferred 
indirectly based on this technique. The histological measure of longitudinal erosion rate (LER), 
or cutting cone advance, has been measured based on the assumption that cutting cone advance is 
equal to that of closing cone advance (Figure 1.5). This measure has only been assessed in two 
	 7 
studies from the 1970s, reporting LERs of approximately 40 µm/day (28, 29). This value has 
been utilized in studies simulating BMU dynamics in silico using predictive, theoretical models 
and computer simulations (30-32). Despite being frequently cited, these classic studies bear 
several limitations. For instance, small sample sizes of mongrel dogs (n = 3-5) were used and 
LER was only assessed in the rib (28, 29). The results also showed a large level of variation in 
the rate of advance as well as the size of the reversal zone between the cutting and closing cone 
(29), indicating variation in BMU activity. This variation indicates BMU behaviour may in fact 
vary considerably across species and bone types and be influenced by external factors. This 
variation is not taken into consideration in the classical histological measure of LER, yet has 





Figure 1.5. A schematic of a longitudinal section of cortical bone depicting a BMU 
analyzed with dynamic histomorphometry. Dual bone fluorochrome labels, which 
incorporate into newly mineralized bone, are administered in vivo to enable the direct 
quantification of closing cone advance, or the amount of bone formed within the 
labelling period (distance between 1nd Label and 2nd Label). Longitudinal erosion rate 
(LER), or the rate of cutting cone advance (distance between Time 1 and Time 2), 
has only been inferred from the rate of closing cone advance, under the assumption 
that the two activities are equal. This histological measure of LER was measured in 




Micro-computed tomography (micro-CT) provides a non-destructive pathway for the 3D 
visualization of cortical bone microarchitecture (33). Micro-CT is an essential imaging tool that 
uses X-rays to visualize skeletal structure in high resolution. A direct, accurate measure of LER 
can be obtained utilizing this high-resolution imaging modality to provide novel 3D and 4D 
information about cortical porosity; however, in vivo imaging is limited by the radiation dose it 
imparts. In order to increase imaging resolution, radiation dose is required to increase 
exponentially (34). Other imaging modalities that can assess bone microarchitecture in vivo, like 
high-resolution peripheral quantitative computed tomography (HR-pQCT), are not capable of 
imaging with high enough resolution to sufficiently resolve all vascular pores. Standard patient 
HR-pQCT operates at an isotropic voxel size of  ~82 µm (35, 36), while newer second-
generation HR-pQCT can image with a higher spatial resolution of ~61 µm (37, 38). These 
systems are ideal for the assessment of trabecular bone microarchitecture, cortical geometry, and 
only the largest of cortical pores in the distal radius and tibia of humans. Combining the use of 
longitudinal, synchrotron-based micro-CT imaging (39) with an appropriate animal model can 
enable the direct tracking of cutting cones in vivo to measure BMU progression. This is achieved 
by the use of a powerful technique known as phase contrast (40), which utilizes the structural 
properties within a sample to generate refraction of monochromatic, coherent synchrotron based 
x-rays (in contrast to absorption of x-rays with conventional micro-CT) when the object is placed 
a certain distance from the detector. The refraction of x-rays increases image contrast and thus 
effective resolution without the expense of high radiation dose. This technique significantly 
improves the detection and in turn, the 3D characterization of cortical porosity and BMU related 
resorption spaces. This platform will allow us to overcome the limitations associated with two-
dimensional (2D) histological studies so we can assess the complex spatio-temporal behaviour of 
BMUs for the first time. Studying bone remodeling in this capacity will provide novel insight 
into how osteoclast function contributes to altering bone microarchitecture since bone 
remodeling dysregulation and variation lie at the root of osteoporosis. Additionally, this 
information will enable the improvement and advancement of therapeutic interventions aimed at 
targeting the OP disease pathway to minimize bone loss. 
 
1.14. Animal Models of Cortical Bone Turnover  
Animal models provide critical platforms for studies investigating factors affecting or 
regulating bone remodeling (41). Particularly, rabbits serve as excellent models to investigate 
BMU behaviour, since they are the smallest laboratory animal to exhibit cortical bone 
remodeling similar to that of humans, as compared to commonly used laboratory mice and rats, 
which exhibit little to no secondary osteons naturally (42-45). Rabbits also have good 
temperament, they exhibit faster bone turnover than primates, and they reach skeletal maturity 
within a relatively short period of time in comparison to larger animal models, at approximately 
6 months old (46). Preliminary proof-of-principal studies conducted by our group have 
demonstrated the feasibility of directly tracking individual remodeling events in rabbit tibiae 
however, these studies revealed that remodeling rates in cortical bone of normal rabbits are low. 
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Furthermore, in general, remodeling rates are lower in cortical bone than to that of trabecular 
bone. In order for a cortical bone model to be operationally effective, there needs to be an 
increase in activation frequency (Ac.f) (47), which is the “birth rate” of new BMUs or the 
frequency with which remodeling is initiated in a given area of bone. Approaches focused 
specifically on cortical bone would establish a viable platform to study the coordination of 
remodeling events and its role in disease progression when utilized in longitudinal in vivo 
imaging studies. Parathyroid hormone is an encouraging and viable pathway for increasing the 
number of potential targets to study BMU activity from given its ability to stimulate bone 
remodeling. 
 
1.2. Thesis Objectives   
 There exists a need for suitable animal models focused on cortical bone to enable the 
study of bone remodeling and its associated porosity. Thus, the primary objective of this thesis 
project was to develop an animal model system of elevated cortical porosity in the rabbit using 
PTH and utilizing micro-CT imaging and histomorphometry to characterize 2D and 3D changes 
in cortical and trabecular bone microarchitecture in the tibiae of PTH-dosed rabbits. This model 
system will be capable of tracking individual remodeling events using longitudinal synchrotron 
based imaging so that we can gain novel insight into the spatio-temporal behaviour of BMUs, the 
very structures involved in the generation of OP, and begin to address the significant knowledge 
gap surrounding bone remodeling dynamics and its role in the development of disease. 
 
1.3. Organization of Thesis 
The research described within this thesis focuses on the development of a rabbit cortical 
porosity model while exploring the effects of PTH on bone microarchitecture. The body of this 
thesis is organized into 3 chapters. Chapter 2 consists of a review of the current literature 
regarding PTH and its effects on bone, providing a rationale for its use in the current thesis 
project to elevate cortical bone porosity in rabbits. This chapter highlights the important role of 
the mode of administration of PTH on trabecular and cortical bone microarchitecture in animals 
and humans, and discusses some of the important mechanisms by which PTH induces its 
anabolic and catabolic effects in bone. This chapter concludes with a brief section on PTH 
effects in rabbit bone to segue into Chapter 3.  
Chapter 3 consists of the main experiment involving the development of the PTH-dosed 
rabbit model. This research is one aspect of a larger study presented as a manuscript entitled 
“Cortical Bone Porosity in Rabbit Models of Osteoporosis” published in the Journal of Bone and 
Mineral Research. The manuscript begins with a recap on bone remodeling and animal models, 
reiterating the importance of developing a cortical bone turnover model before proceeding into 
the experimental manipulation of remodeling events. The manuscript aims to characterize 3D 
cortical porosity changes in the PTH dosed rabbit model in addition to several other rabbit-based 
models of OP (ovariectomy and glucocorticoid induced). Cortical bone microarchitecture is 
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compared amongst the models to determine the rabbit model best suited for future longitudinal in 
vivo imaging studies. These rabbit models were developed in parallel to minimize the need for 
control animals, minimize costs, and convenience. Another graduate student, Kim Harrison, 
characterized the other rabbit based models although, we both equally contributed to the 
experiment and the manuscript in its entirety. As such, we share joint first authorship on this 
manuscript.  
Chapter 4 consists of a brief overview of Chapter 2 and 3 and the future directions of this 
thesis project, discussing potential avenues of research utilizing the PTH dosed rabbit model in 
order to better understand cortical bone remodeling. This chapter also contains some of the 
additional histological work I carried out during my research program as it contributes to future 
directions aimed at reproducing the classic histological measure of LER. 
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CHAPTER 2. Parathyroid Hormone Effects on Bone 
 
2.1. Introduction 
Parathyroid hormone, an endogenous hormone involved in calcium and phosphate 
homeostasis, acts on multiple organ systems to increase calcium levels in the blood when they 
are low. In addition to acting directly on the kidney and indirectly on the intestine to increase 
calcium uptake, PTH acts on the skeletal system by stimulating both bone resorption and bone 
formation, thereby increasing bone turnover overall (48). Parathyroid hormone acts directly on 
members of the osteoblast lineage through binding of the PTH-1 receptor and indirectly on 
osteoclasts to increase the number and activity of both cell types (49). Increased resorption is 
predominantly achieved through osteoblastic-mediated synthesis of the cytokine receptor 
activator of nuclear factor kappa-β ligand (RANKL), which binds to its receptor RANK on 
osteoclasts and osteoclast precursors, and by a decrease in osteoprotegerin (OPG), a decoy 
receptor inhibiting the action of RANKL, together increasing osteoclastogenesis (50). On the 
other hand, increased formation can be partly explained by elevations in osteoblast number 
through multiple mechanisms that modulate the function of osteoprogenitor cells, osteoblasts, 
osteocytes, and bone lining cells (51). The specific cellular and molecular mechanisms that 
underlie this increased formation are currently not fully understood. Interestingly, it has been 
shown that PTH imparts distinct effects on the skeleton depending on the amount of circulating 
PTH in the blood. Generally speaking, intermittent administration of PTH increases bone 
formation, resulting in a net gain in bone mass, whereas high circulating levels of PTH, as seen 
in patients of hyperparathyroidism or with continuous administration in animal studies, results in 
a net loss of bone mass (48). This review will focus on the dual action of PTH on bone, 
highlighting some of the pivotal work that has been carried out in animal (mice, rats, rabbits, 
dogs, monkeys) and human clinical studies, and offering several plausible explanations for the 
distinct outcomes observed with intermittent and continuous PTH dosing regimens and for the 
variation observed with some of the bone responses to PTH.  
 
2.2. Intermittent PTH  
Since the discovery of its anabolic properties on bone (52), intermittent PTH has been 
studied in basic and translational studies utilizing intact/normal and OP animal models, as well 
as in clinical studies. Repeated transient exposures of bone to PTH and its analogues, particularly 
the N-terminal fragment of the intact hormone (PTH (1-34)), the bioactive portion of the 
hormone, leads to bone apposition and thus, increased bone mass. Low, intermittent doses of the 
recombinant protein form of PTH (1-34), known as teriparatide, have been employed as one of 
the only clinical anabolic treatments indicated for OP in postmenopausal women (53-63), elderly 
men (61, 63, 64), pre-menopausal women with idiopathic OP (65), and patients with GC induced 
OP with high risk of fracture (66). Parathyroid hormone’s anabolic capabilities have also been 
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exploited recently to stimulate and accelerate bone healing with bone grafts and implants in 
animal studies (67-70). The current literature has revealed intermittent PTH administration as 
promoting bone formation on trabecular, endosteal, and periosteal (the outer surface of a bone) 
surfaces, while increasing intracortical porosity in the axial and appendicular skeleton, although 
there is heterogeneity in terms of trabecular and cortical bone responses.   
 
2.21. Intermittent PTH Effects in Trabecular Bone  
 In trabecular bone, intermittent PTH administration has been shown to increase BMD as 
assessed by dual-energy X-ray absorptiometry (DXA) and HR-pQCT within trabecular rich sites 
of animals (71-73), and postmenopausal women (55, 56, 59, 74-76). This increase in BMD is 
related to improvements in trabecular bone architecture, which is based on studies utilizing 
histology or various imaging modalities like standard computed tomography (CT), pQCT, HR-
pQCT, and micro-CT. PTH increases trabecular bone volume (trabecular bone volume fraction; 
BV/TV) (55, 61, 67, 77-80), the number of trabeculae (trabecular number; Tb.N) (67, 74, 79-82), 
and the thickness of trabeculae (trabecular thickness; Tb.Th) (55, 78, 81, 83), and decreases the 
distance between trabeculae (trabecular separation; Tb.Sp) (67, 79, 80, 82), all contributing to the 
elevation of bone mass. In addition to improving trabecular microarchitectural parameters, 
trabecular strut analyses have revealed PTH also increases trabecular connectivity in animal 
models (68, 77, 79) and clinical patients (59). The improvement in trabecular bone 
microarchitecture contributes to the overall strength and stiffness of bone and renders it more 
efficient in bearing mechanical loads.  
Bone formation is typically evaluated in bone biopsies by dynamic histomorphometry, 
which involves the assessment of dual fluorochrome labels administered at discrete time points 
in vivo prior to sacrifice. These parameters include mineralizing surface per bone surface 
(MB/BS), mineral apposition rate (MAR), and bone formation rate (BFR) which can all be 
measured on trabecular, endosteal, and periosteal surfaces as well as in intracortical osteons (84) 
(Figure 2.1). Mineralizing surface per bone surface describes the extent of mineralization on a 
bone surface at a particular time measured as the sum of the total extent of double label and half 
the extent of the single label, divided by the total bone surface. Mineral apposition rate 
represents the linear rate of new bone deposition, measured as the distance between two 
consecutive fluorochrome labels divided by the labelling period. When quantified in a 
longitudinal section of a BMU, this measure can be utilized to infer LER histologically (Figure 
1.5) (28, 29). Bone formation rate is the amount of mineralized bone formed per unit time, 
calculated as the product of MAR and MS/BS. Bone formation in the trabecular compartment is 
reflected by increases in these histomorphometric parameters of bone formation (54, 57, 58, 62, 
71, 77, 82, 83). Activation frequency, a fundamental measure of remodeling rate previously 
defined in Chapter 1, has also been shown to increase in trabecular bone (62, 63, 75, 83, 85), 




Figure 2.1. Confocal micrograph of a histological transverse section of cortical bone 
depicting fluorescent bone labels (green). Primary histomorphometric measures of 
bone formation activity can be quantified from these fluorochrome labels that appear 
on periosteal and endosteal surfaces and in intracortical BMUs. They can also be 
measured on trabecular bone surfaces. Mineralizing surface per bone surface 
(MS/BS) is measured as the full extent of double labelled bone surfaces plus half the 
extent of single labelled bone surfaces, normalized to the total bone surface. Mineral 
apposition rate (MAR) can be measured from double labelled surfaces as the distance 
between two fluorochrome labels divided by the time between label administrations. 




 Not all studies evaluating intermittent PTH have found increases in trabecular bone 
formation as some groups have reported a lack of change in Tb.Th (71, 80, 82), and one study 
reported decreases in BMD, Tb.N, and BV/TV within the radius of postmenopausal women with 
OP treated with 20 µg/day PTH for 18 months (53). This variation in responses may be 
explained by a number of reasons. The lack of change in Tb.Th may have been a result of 
resorption occurring within the trabeculae, as several groups have reported trabecular tunnelling, 
with intermittent PTH doses (55, 79, 80, 85, 86). This resorption would divide existing 
trabeculae that were initially thickened by bone accrual early in treatment, which could explain 
the increase in Tb.N typically reported in these studies. Trabecular tunnelling does however, 
seem to occur with the administration of high PTH doses (55), with continuous PTH 
administration (78), and with long, extended courses of treatment (79, 80), therefore it is not 
clear if tunneling is the result of excessive resorption or occurs as an adaptive response to PTH 
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associated trabecular thickening. The dose and timing of PTH may also be a factor in the varying 
trabecular outcomes seen with intermittent PTH, as significant increases in Tb.Th seen after 35 
days of PTH dosing in rabbit lumbar vertebrae were diminished after 70 days (83). It is not clear 
if this diminished effect was a result of trabecular tunneling since Tb.N was not assessed in the 
study. Similarly, in a longitudinal, prospective clinical study, Hansen and colleagues found Tb.N 
to be increased in postmenopausal women after 6 months of daily PTH treatment at a 20 µg dose 
but this decreased with continued treatment at 18 months (74). Dose frequency of PTH may also 
influence trabecular outcomes as Yamamoto and colleagues found that more frequent dosing of 
PTH (up to 4 times per day) resulted in thinner trabeculae in the mouse femoral metaphysis 
while less frequent, once daily dosing of PTH resulted in thicker trabeculae (67). Variation in 
trabecular outcomes with intermittent PTH may also be related to the site of study. Anabolic 
effects of PTH are evident in skeletal sites rich in trabecular bone such as the iliac crest, lumbar 
spine, femoral neck, mandible, and proximal tibia, but not in the middle or distal radius (55, 73, 
74). One study reported reductions of BMD in the distal radius of postmenopausal women 
treated with daily PTH (20 µg) for 18 months (74). The lack of bone formation at the radius may 
be due to its tissue composition, as these regions are rich in both cortical and trabecular bone, 
however it is not clear why these bone site specific differences exist. 
 
2.22. Intermittent PTH Effects on Endosteal and Periosteal Surfaces    
 On endosteal and periosteal surfaces, PTH induces similar effects to that of trabecular 
bone, stimulating bone apposition as revealed through histomorphometric fluorochrome labelling 
studies on bone biopsies. Increases in MS/BS (57, 58, 87), MAR (57, 58, 71, 83, 85, 88), and 
BFR (57, 58, 71, 83, 85, 88) have been reported on one or both surfaces. Formation generally 
occurs to a greater extent on the endosteal surface than that on the periosteal surface (58, 71). 
This is probably due to the fact that the adjacent vascular marrow cavity readily provides a rich 
source of cells. The significant mineralization of these surfaces is associated with changes in 
cortical geometry demonstrated by increases in cortical thickness (Ct.Th) (55, 59, 74, 75, 79, 87-
89), cortical area (Ct.Ar) (71, 87, 88), and total area (Tt.Ar) (71, 74, 88). While some groups 
have reported decreases in marrow area (Ma.Ar) (88), others have found no changes in this 
parameter (71, 87). These data indicate bone is forming on both surfaces, and this accrual of 
bone may contribute to elevations in BMD (83). As indicated in trabecular bone focused 
experiments, differences in cortical geometry outcomes may be specific to certain bone sites. 
Despite a reduction in BMD in the radius, total area was slightly elevated in postmenopausal 
women treated with daily PTH (20 µg) for 18 months but no change was observed in the tibia 
(74). Within this study, it was unclear whether the increase in area was due to bone apposition or 
related to the HR-pQCT methodology where the region of interest between baseline and follow-
up scans was determined by a common region matching procedure which assumes constant area 
over time. It may be the case that the imaging methodology employed introduced an additional 
variable into bone architectural analysis and therefore, the apparent variation observed may not 
be accurate.   
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2.23. Anabolic Effects & Timing 
 The magnitude of the anabolic effects induced on bone surfaces by PTH not only depends 
on mode (intermittent vs. continuous) and dose (low vs. high), but also on the length of PTH 
administration and the time within the course of the treatment that the bones are analyzed (early 
vs. late in treatment). It has been shown that low intermittent dosages of PTH stimulate bone 
formation early in treatment, as evidenced by an early rise in bone formation markers, followed 
sometime thereafter by a rise in both bone formation and resorption markers (62). If bone 
markers reflect physiological actions, then it is likely from these studies that modeling based 
bone formation, formation that occurs in the absence of resorption, predominates at this early 
stage, with the proportions of remodeling based bone formation to modeling based formation 
increasing with long term intermittent PTH treatment (54, 63). Modeling based bone formation 
has been reported in several human clinical (57, 58, 63, 90) and animal (91) studies as revealed 
by histological staining of cement lines. Lindsay and colleagues found that bone formation 
induced by PTH was 70% remodeling based and 30% was modeling based within the iliac crests 
of postmenopausal women with OP treated with PTH for one month in comparison to age-
matched controls which exclusively exhibited remodeling based bone formation (57). The time 
frame for which PTH is maximally anabolic is termed the “anabolic window” and occurs within 
the first 9-12 months of clinical PTH treatment (92-94). Long term PTH administration is 
associated with declining anabolic effects, which may be related to the level of the protein 
Dickkopf-1 (DKK1), a potent regulator of osteoblast activity. Increasing serum levels of DKK1 
have been shown to be associated with a decrease in bone formation markers in postmenopausal 
women after receiving daily PTH (20 µg) for 18 months, although levels of these markers were 
still significantly higher than baseline (95). The proportion of remodeling to modeling based 
bone formation may also be dependent on dosing frequency as Yamamoto and colleagues found 
that the modeling based bone formation prevalent on quiescent trabecular surfaces within the 
femoral metaphysis of mice treated with once daily PTH was diminished with increased 
administration of PTH, of up to 2-4 times per day, which probably favoured bone remodeling 
(67).  
 Modeling based bone formation not only occurs on previously quiescent bone surfaces 
but also on existing, actively remodeling BMUs where modeling based bone formation “spills 
over” onto quiescent surfaces (57, 58, 90). In a quadruple bone fluorochrome labeling study, 
modeling was observed in hemi-osteons within trabecular and endosteal bone of postmenopausal 
women treated with PTH for one month. Hemi-osteons were classified based on the 
characteristics of their cement lines and collagen fiber orientation. As such, structures were 
termed remodeling hemi-osteons, modeling hemi-osteons, and mixed modeling-remodeling 
hemi-osteons (90). Within mixed modeling-remodeling osteons, the mineralized perimeter (the 
second double fluorochrome bone label) increased in length indicating bone formation extended 
beyond the original boundaries of the scalloped cement line onto adjacent, previously unresorbed 
quiescent surfaces (58). As a result of this “overfilling”, trabecular and endosteal hemi-osteonal 
wall thickness increase, demonstrating PTH’s ability to induce a positive bone balance (90). 
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Overall, the early mechanism of anabolic action of PTH is the initiation of bone remodeling 
based bone formation as well as modeling based bone formation.  
 
2.24. Cellular Mechanisms of Bone Apposition 
 At the cellular level, the extent of bone formation is largely determined by the number of 
osteoblasts, which in turn, is determined by the rate of replication of osteoblast precursors and 
the life span of mature osteoblasts. A significant proportion of the anabolic effects of intermittent 
PTH on trabecular, endosteal, and periosteal surfaces are mediated by increases in osteoblast 
number. Osteoblasts have 3 fates: to become osteocytes encased by mineralized bone, to become 
quiescent bone lining cells, or to undergo apoptosis. Amplification of osteoblast number by 
intermittent PTH has been associated with increases in the differentiation of osteoblast 
precursors (96, 97), the survival of osteoblasts (98-100), and the mobilization of bone lining cells 
(101). Several cellular mechanisms have been proposed which mediate these anabolic effects 
involving increases in growth factors (insulin like growth factor 1 (IGF-1), transforming growth 
factor-β (TGF- β), and bone morphogenic proteins), which increase the differentiation and 
survival of osteoblasts, increase in the expression of runt-related transcription factor 2 (Runx2), a 
transcription factor involved in the regulation of osteoblast differentiation and survival of 
osteoblasts, and activation of mammalian homologue of wingless-related integration site in 
drosophila (Wnt) signalling, which regulates osteoblast proliferation and differentiation (51). 
Apposition on bone surfaces may also be achieved by increases in angiogenesis (102) and 
through osteocyte mediated sclerostin inhibition (103, 104), as the glycoprotein is known to 
inhibit bone formation. These are just a few of the notable pathways involved in the vast 
signalling network activated by PTH therefore, further investigation is required to fully 
understand and appreciate PTH’s anabolic effects.  
 The mechanisms noted above appear to affect trabecular and cortical bone compartments 
to different extents, which may explain some of the differences observed on the bone surfaces 
with intermittent PTH administration. For instance, Jilka and colleagues found that the 
predominant mechanism of osteoblast number increase in trabecular bone was through the 
attenuation of osteoblast apoptosis, which they studied in PTH treated transgenic mice vertebrae 
(100). On the periosteal surface, this mechanism did not substantially contribute to the increase 
in osteoblast number since the rate of osteoblast apoptosis was low in that region and therefore, 
did not have much of an effect. The increase in osteoblast number on the periosteal surface was 
accounted for by the increase in the differentiation of osteoblast precursors (100). The increase in 
osteoblast number on the periosteal surface is further elevated by the reactivation of bone lining 
cells. In an in vivo lineage tracing study, PTH increased osteoblast number by converting bone 
lining cells to active osteoblasts on the quiescent periosteal surfaces of calvaria (parietal bones) 
in transgenic mice treated with 80 µg/kg PTH for 3 days (101). This reactivation of bone lining 
cells into mature osteoblasts is one of the primary mechanisms underlying modeling based bone 
formation seen early in intermittent PTH treatment. These studies suggest that skeletal 
compartment (trabecular, endosteal, periosteal, intracortical) specific responses to intermittent 
	 17 
PTH may be a result of osteoblast progenitors responding differently to PTH, although there may 
be many cellular mechanisms at play.   
 
2.25. Intermittent PTH Effects on Intracortical Bone  
Despite increases in bone formation on trabecular, endosteal, and periosteal surfaces, 
intermittent PTH has been shown to increase cortical porosity (Ct.Po) assessed using histology 
(55, 71, 79, 87, 105), HR-pQCT (53, 74), and more recently, ex vivo conventional micro-CT (89, 
106) within the appendicular skeleton. Cortical porosity has also been reported in the outer shell 
of the iliac crest of postmenopausal women (54), and in the rib of dogs (85). This increase in 
porosity is due to PTH’s ability to increase bone remodeling in cortical bone as evidenced by an 
increase in Ac.f (71, 79, 83, 87). PTH has also been shown to increase bone formation 
intracortically by increasing osteonal MAR (On.MAR) (63, 87) and BFR (71, 79, 87). There is 
concern that high proportions of intracortical porosity would increase the risk of fragility and 
therefore fractures in OP patients, but animal and clinical studies have demonstrated intermittent 
PTH preserves (74, 83, 87, 89, 91) and even improves (71, 79, 105) bone strength in long bones. 
It has also been reported that intermittent PTH reduces incidences of vertebral (56, 66) and non-
vertebral (56, 107) fractures in populations of OP patients. This maintenance of bone strength 
imparted by intermittent PTH can be explained by two possible reasons. First, it may be that 
intracortical porosity is compensated by increases in cortical geometry through endosteal and 
periosteal bone apposition thereby limiting negative biomechanical impacts. A key determinant 
of bone strength is its geometry, or the bone’s overall size and shape. Bone strength is also 
dependent on the amount of bone present. Small increases on the periosteal surface of bones 
especially improves strength since the diameter of a bone is proportional to the moment of 
inertia, or the bending resistance of bone (108). Hirano and colleagues found the cross sectional 
moment of inertia to be increased despite a 3.8% increase in Ct.Po in tibiae of rabbits treated 
with 40 µg PTH/kg/5 days a week for 140 days. The gain in strength was associated with an 
increase in Tt.Ar (105). Similarly, an increase in Ct.Po and Ct.Ar in the humerus of OVX 
cynomolgus monkeys treated with 5 µg PTH/kg/day for 18 months did not have an effect on 
extrinsic mechanical parameters (ultimate load, stiffness, work to failure) in comparison to OVX 
controls (87). This outcome has also been reported clinically, as Hansen and colleagues found 
bone strength, estimated by finite element analysis, to be preserved in the radius and tibia of 
postmenopausal women with OP treated with daily PTH (20 µg) for 18 months despite reporting 
increases in Ct.Po (74).  
The second reason bone strength may not be negatively impacted by PTH despite 
elevations in intracortical porosity is that the porosity frequently exhibits a non-random 
distribution throughout the cortex, predominantly occupying the region near the endosteal 
surface (83, 87, 91, 105, 106, 109, 110). This distribution of pores in this region aids in offsetting 
the negative impact of increased intracortical porosity on biomechanical strength, since the loss 
of bone is closest to the bone’s neutral axis of bending (87, 105), which minimizes the risk of 
fracture by modulating the impact on the resistance to bending and torsional loads (108). 
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Localization of pores within certain regions along the endosteal surface may further contribute to 
offsetting potential biomechanical impacts as porosity was seen to be localized within 
anteromedial and posterolateral sites of the tibia in rabbits treated with 40 µg PTH/kg/day for 4 
weeks (89). This pattern occurs within cortical bone of larger animal systems and humans, 
however, porosity was pronounced near the endosteal surface in the tibiae of rats (109), a species 
known to generally exhibit little to no spontaneous cortical remodeling. The pores observed in 
these rats were likely not “true” intracortical pores as they were continuous with the medullary 
cavity. Furthermore, in rats, it may be the case that this phenotype only occurs with exposure to 
high circulating levels of PTH, since within the same study, porosity was non-existent in rats 
treated with intermittent PTH. This raises the question whether PTH-driven species-specific 
cellular mechanisms involved in the development of cortical porosity are at play. The non-
random distribution of porosity accompanied by geometrical changes of cortical bone may be 
part of the explanation as to why the integrity of the bone’s biomechanical properties were 
maintained, despite elevations in intracortical porosity. These effects are particularly important 
in bones of the appendicular skeleton since they withstand high mechanical loads. Further 
investigation into the impact of cortical porosity and geometry by PTH on biomechanical 
properties of cortical bone is certainly warranted. 
Overall, the literature has shown intermittent PTH stimulates bone apposition on 
trabecular, endosteal, and periosteal surfaces while increasing intracortical porosity. Increased 
intracortical porosity is primarily due to elevated remodeling while bone surface apposition is 
due to increased remodeling (with a net positive balance) in addition to early modeling based 
bone formation. The precise cellular and regulatory mechanisms that initiate these actions on the 
skeletal envelopes are largely unknown and warrant further study. 
 
2.3. Continuous PTH Effects on Cortical and Trabecular Bone 
 While intermittent PTH accelerates bone turnover creating a net positive bone balance, 
observations of patients with hyperparathyroidism and animals receiving continuous PTH 
administration (delivered via osmotic pumps), show that PTH at sustained elevated levels 
induces predominantly catabolic effects in bone. This is a consistent finding for only cortical 
bone as the effect in trabecular bone is controversial. In cortical bone, continuous infusions of 
PTH result in increased Ct.Po (111, 112), decreased BMD (112, 113), and thinner cortices (114, 
115) as bone resorption in elevated on the endosteal surface. One study in rats found Ct.Ar to be 
maintained and accompanied by increases in mineralization on the endosteal and periosteal 
surfaces and no deleterious effects on bone strength (111). It is worth noting that the clearance 
from serum of biologically active PTH may play a role in its effects on bone, which in turn can 
influence the significant changes observed, since some species may metabolize the hormone 
more quickly than others. Parathyroid hormone clearance in rats is approximately 1 hour after 
subcutaneous PTH injection (82), whereas PTH clearance in humans is approximately 4 hours 
(116), although this may be altered by a number of factors including age and health. One should 
consider the role that species-specific physiological mechanisms play in pharmacokinetics and 
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therefore, PTH administration should to be adjusted in animal studies accordingly to better 
mimic the PTH dose delivered clinically.  
 In trabecular bone, there is a lack of consensus on the effects continuous PTH has in this 
bone compartment. Some studies in patients with PHPT and in animals receiving continuous 
infusions of PTH have indicated preservation and apposition of trabecular bone with continuous 
PTH (78, 82, 109, 111, 114, 117), while others have reported losses of trabecular bone mass (81, 
112, 115). One group even found improvements in trabecular architectural parameters (increase 
in BV/TV, Tb.N, and decrease in Tb.Sp) within PHPT patients (114). In those studies reporting 
apparent maintenance or increases of trabecular bone, pronounced mineralization was observed 
(78, 111, 117) indicating prevalent bone formation. Conversely, at high doses, some have 
reported the appearance of woven bone (78, 111) and trabecular tunnelling (78) in trabeculae of 
rats receiving osmotic infusions of PTH. In some instances, continuous infusions of high dose 
PTH in rats have even resulted in high rates of hypercalcemia as a result of elevated bone 
resorption and death (81, 82). Variation in trabecular bone outcomes in response to continuous 
PTH may be related to the relative amount of trabecular bone present at the skeletal site, as 
similarly observed with intermittent PTH. This is illustrated by a study of PHPT patients where 
losses of bone were observed to have occurred in a cortical and trabecular bone rich site, the 
radius, while the trabecular bone-abundant lumbar vertebrae was maintained, and the femoral 
neck, which has a mixed composition of cortical and trabecular bone, had an intermediate effect 
(113). Interestingly, Uzawa and colleagues found losses in the rat tibial diaphysis and epiphysis 
with infusions of 2.14 ng/hr or 214 ng/hr PTH for 4 weeks, but increases in trabecular bone 
volume (BV/TV) in the tibial metaphysis (78). It is important to note that the morphology of 
trabecular bone at this site in rats was abnormal. Despite its apparent preservation, abnormal 
trabecular morphology can negatively impact the quality of bone, which in turn affects the 
overall bone strength in that compartment.  
 The apparent maintenance of trabecular bone in PHPT patients may be an artificial result 
as many of the imaging modalities utilized to measure bone microarchitectural outcomes in 
clinical studies (ie., DXA) do not distinguish between cortical and trabecular bone 
compartments. In a HR-pQCT study of cortical and trabecular bone in 43 PHPT patients (male 
and female, mean age 63 years old), Vu and colleagues speculated that remodeling near the 
endosteal surface results in both the development of porosity intracortically and the erosion of 
the endosteal surface, together creating structures resembling trabeculae and thus, enlarging the 
medullary cavity. These “cortical remnants” are usually included in the quantification of 
trabecular BMD as these are not distinguishable from true trabeculae with standard imaging 
modalities and therefore, there is an overestimation of trabecular BMD (112). It should be noted 
that the “trabecularization” of the cortex is associated with advancing age (21) therefore, it may 
be the case that several mechanisms of bone loss contributed to the thinning of cortices in PHPT 
subjects. The degree to which this effect occurs in animals or younger PHPT patients remains to 
be elucidated.  
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The periodicity of PTH administration, intermittent vs. continuous, is one of the 
prevailing factors that determine the outcome in cortical and trabecular bone, and the current 
literature has overwhelmingly supported this. It has been suggested that the two modes of 
administration regulate different sets of genes as indicated by gene expression profiling (118) 
although many additional mechanisms may also be at play. Some of the cellular mechanisms that 
contribute to these differences involve relative levels of Runx2 and RANKL/OPG. With regards 
to the former, intermittent PTH has been shown to temporarily decrease Runx2 protein levels, 
thereby repeatedly delaying osteoblast apoptosis with each exposure. Runx2 mediated 
transcription of pro-survival genes by intermittent exposures of PTH is short lived because of 
subsequent feedback inhibition back on PTH which then stimulates the degradation of the 
transcription factor. In an in vitro study, a continuous infusion of PTH on cultured osteoblast 
cells was shown to decrease Runx2 protein levels below a critical threshold needed to sustain the 
anti-apoptotic signalling, thereby terminating the pro-survival effect on osteoblasts, while 
intermittent PTH levels increased Runx2 levels transiently (98). The duration of the anti-
apoptotic effects of PTH appears to be dependent on the protein level of Runx2, which illustrates 
the importance of employing intermittent PTH to stimulate bone formation. As shown in vivo 
and in vitro, continuous PTH circulation has also been shown to prolong and sustain the 
expression of RANKL levels while inhibiting OPG, thereby increasing osteoclast differentiation 
and lifespan and promoting bone resorption (119, 120). Under intermittent conditions, PTH only 
induces a transient change in RANKL and OPG (119) or no alteration at all (120). While the 
increase in resorption can be partially explained by these pathways, the catabolic and anabolic 
effects of PTH likely involve many signalling pathways and cells and the current knowledge of 
these mechanisms are limited and require further investigation.  
 
2.4. PTH Effects on Rabbit Bone 
 The rabbit has been an important laboratory animal model for assessing PTH affects on 
bone, since its cortical bone undergoes remodeling similar to that of humans and it responds 
remarkably well to PTH. The rabbit has been a better model system to assess bone ingrowth into 
implants and with bone grafts because their bones are greater in size than that of mice and rats. 
These studies have utilized PTH’s anabolic effect to promote bone healing and the incorporation 
of implants and grafts into bone (67-70). As discussed in sections 2.21 - 2.25, intermittent 
dosages of PTH have been shown to increase intracortical porosity while stimulating bone 
apposition on trabecular, endosteal, and periosteal surfaces in the rabbit, albeit there is variation 
within some bone microarchitectural outcomes (71, 83, 89, 91, 105, 106). Within cortical bone, 
improvements in bone geometry induced by PTH have been shown to maintain and even 
strengthen cortical bone despite elevations in intracortical porosity (71, 83, 105). Currently, 
information regarding the effect of continuously high circulating levels of PTH on rabbit bone is 
limited, being reported in only two studies (121, 122). Within these studies, PHPT was 
experimentally induced in rabbits using a high phosphate diet, and the presence of the disease 
was confirmed by histopathological analyses of the parathyroid glands, kidney, and bone. While 
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bone fibrosis was noted, these studies did not extensively characterize cortical or trabecular bone 
microarchitectural changes in these rabbits. Future studies are needed to optimize rabbit models 
of PHPT, particularly with respect to bone microarchitecture.  
Much of the work that has characterized changes in cortical and trabecular bone 
microarchitecture due to intermittent PTH in the rabbit have employed standard static histology 
and dynamic histomorphometry. Recently, several groups have utilized desktop micro-CT to 
investigate the effects of PTH dose frequency on cortical bone microarchitecture in rabbits (89, 
106). These studies imaged rabbit bone with an isotropic voxel size of 15-20 µm. It would be 
beneficial to image rabbit cortical bone at a higher spatial resolution in order to acquire more 3D 
information on its porosity so that we can better understand how PTH affects bone remodeling. 
Given that PTH has well-documented effects on cortical bone in the rabbit, the hormone can be 
employed to increase intracortical porosity in animals that typically have low levels of bone 
turnover to establish a viable model system that is currently lacking in the literature.  
 
2.5. Conclusion  
Overall, PTH is a potent stimulator of bone remodeling in cortical and trabecular bone. 
Intermittent PTH increases bone formation, thereby increasing bone mass and improving 
microarchitecture. Conversely, excess PTH shifts remodeling to increased resorption rather than 
formation leading to the deterioration of bone microarchitecture. Variation does exist in 
trabecular and cortical bone’s response to PTH. Parathyroid hormone increases porosity in larger 
animals capable of remodeling their bones and humans with both modes of administration by 
initiating new remodeling events and increasing the rate of remodeling. Parathyroid hormone can 
therefore be utilized to increase cortical bone remodeling in animal model systems with low rates 
of bone turnover, like in the rabbit tibiae, as mentioned in section 1.4, to maximize the number of 
potential targets to study BMU activity from within a small section of bone using in vivo high-
resolution longitudinal imaging. Intermittent PTH can increase the number of new BMUs in 
cortical bone while minimizing adverse effects associated with high circulating levels of the 
hormone (ie. hypercalcemia) and even offer benefits like bone apposition on the trabecular, 
endosteal, and periosteal surfaces to offset potential detrimental effects on bone strength. For this 
reason, PTH was employed in my thesis project to establish a cortical bone model in the rabbit, 
providing a platform for the study of bone remodeling and associated cortical porosity.  
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CHAPTER 3. Cortical Bone Porosity in Rabbit Models of Osteoporosis 
 
This chapter consists of the manuscript entitled “Cortical Bone Porosity in Rabbit Models 
of Osteoporosis” published in the Journal of Bone and Mineral Research. The manuscript aims to 
describe 3D cortical porosity changes in the PTH rabbit model in addition to several other rabbit-
based models of OP (ovariectomy and glucocorticoid induced), which have been characterized 
by Kim Harrison (doctoral student). As Kim and I have equally contributed to the work 
presented in this manuscript, we share joint first-authorship. Contributions to the manuscript 
have also been made by the following co-authors: Arash Panahifar, Amir Ashique, Janna 
Andronowshi, Gavin King, Kurtis Swekla, Terra Arnason, Peter Pivonka, and David Cooper. 
The discussion of data within this manuscript has been written to adhere to the guidelines set by 
the Journal of Bone and Mineral Research such that results are reported to reflect a more 
thoughtful interpretation of all the data presented and avoid dichotomous use of the p value. This 
manuscript is a previous revision to the accepted version online and has been reformatted for 
inclusion in this thesis. 
 
3.1. Introduction 
Globally, 200 million people live with OP (123), which places significant burdens on 
health care systems worldwide. Assessment of osteoporotic bone loss has classically focused on 
bone mass and density at common fracture sites such as the hip, wrist, and lumbar vertebrae; 
however, there is growing recognition of the role of microarchitecture in bone deterioration and 
fragility (124). This trend has been driven by advances in imaging which have enabled 
assessment of microarchitecture – particularly for trabecular bone. More recently, imaging 
approaches to assess cortical bone microarchitecture (porosity) have emerged for both preclinical 
(animal model) and clinical assessment (33, 125), creating the potential to move beyond what 
has been termed a ‘trabeculocentric’ view of bone loss (126). Indeed, the majority of the 
appendicular skeleton is comprised of cortical bone which suffers from significant losses 
associated with age (18, 126, 127). Moreover, 80% of all fractures occur at sites of weakened, 
thinned cortical bone (19, 20). As recently reviewed, cortical bone porosity is associated with the 
mechanical strength of bone and is negatively related to material stiffness, toughness, and the 
capacity of bone to absorb impact (125).   
     An increase in cortical porosity, at the scale of vascular pores (e.g. osteonal/Haversian 
canals and associated resorption spaces), is a physical manifestation of bone loss that arises as a 
result of an imbalance in cortical remodeling with bone resorption outweighing bone formation. 
Remodeling, in the strict sense that Frost defined, refers only to the creation of secondary tissue 
(turnover) in either cortical or trabecular bone. The cells responsible for an individual 
remodeling event are referred to as a BMU (4). Basic multicellular units are activated on bone 
surfaces, leading to the replacement of cylindrical packets (secondary osteons) in the cortex and 
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trench-like packets (hemi-osteons) in trabecular bone (8). Within cortical bone, BMUs are 
classically depicted as consisting of an osteoclastic cutting cone which creates a tunnel-like 
resorption space followed by an osteoblastic closing cone. A reversal zone separates them, but 
the two processes are spatially and temporally ‘coupled’ (128, 129) and continued resorption has 
been demonstrated in this “reversal-resorption” phase of the BMU (130). Imbalance with 
resorption outweighing formation within individual remodeling events is the underlying 
mechanism by which cortical porosity increases with age and/or disease. Increases in cortical 
porosity may be either a product of increased rate of remodeling, where formation lags behind 
resorption (131) also referred to as “transient remodeling spaces” (132), or through “uncoupling” 
where there is an arrest during the reversal phase of the BMU (133-135). Strategies for the 
prevention and/or reversal of OP ultimately must seek to augment the balance between 
resorption and formation within individual BMUs and not simply the cessation of remodeling as 
reflected by the growing body of literature on the side-effects (e.g., osteonecrosis of the jaw, 
atypical fractures) of some anti-resorptive therapies for OP - mainly bisphosphonates, but also 
recently reported for Denosumab (136-140). High-resolution pre-clinical imaging of the 
resorptive phase of individual BMUs holds great promise for novel spatial-temporal assessment 
of BMU regulation, both ex vivo (141) and even in vivo (33, 39).  
Given that cortical bone porosity is intimately linked with the remodeling process, is of 
clinical relevance, and presents an increasingly accessible target for imaging, there is a growing 
need for suitable animal models of OP to advance our understanding of how cortical porosity 
develops and how it is impacted by countermeasures. Inter-species variation in cortical 
microarchitecture can, however, limit the utility of common animal models. The cortical bone of 
larger vertebrates, including humans, tends to be dominated by secondary bone that is generated 
by remodeling while smaller species (mammals under 2 kg (142)), including mice and rats 
exhibit little, if any, cortical turnover and thus retain primary vascular canals throughout their 
lives (42, 43, 45, 143, 144). Because of this, the American Food and Drug Administration (FDA) 
recommends the use of larger animals which remodel their cortices in addition to the common 
OVX rat model for OP studies (145). Notably, larger species including rabbits, sheep, goats, 
dogs, and swine have all been employed in OP research (42, 43, 45, 144). Here we focus on the 
rabbit, the smallest commonly employed laboratory animal with well-defined spontaneous 
cortical remodeling similar to humans (44, 146, 147). Rabbits also have the advantage of a 
remodeling period that is shorter than larger animal models, a relatively rapid skeletal maturation 
(by 6–9 months) (148, 149), and they are known to respond to PTH treatment with elevated 
remodeling and cortical porosity (71, 105, 106, 150). Taken together, these characteristics make 
the rabbit a promising platform for OP studies which is well suited for potential in vivo imaging 
(151) in future studies.  
 Animal models of OP generally focus on OVX to simulate post-menopausal decline in 
estrogen. In rabbits, however, the efficacy of this model is uncertain. OVX alone has been 
reported by several groups as ineffective at inducing OP in the rabbit (152-154), while others, 
conversely, have reported significant reductions in BMD (155-158). The efficacy of the rabbit 
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OVX model for induction of cortical porosity, in particular, is uncertain as existing studies have 
primarily focused on trabecular bone. The administration of GC either alone or, more commonly, 
in combination with OVX (OVX+GC) is a proven approach for inducing trabecular (152-154, 
159-162) and cortical geometry/density changes (153, 161) in the rabbit. That said, the impact of 
GC alone on cortical bone porosity in the rabbit has not yet been assessed and cortical porosity 
outcomes for OVX+GC have only recently been explored (163). Rabbit OP models hold great 
potential as platforms for advancing our understanding of cortical remodeling and associated 
porosity; however, this potential can only be realized by filling these gaps in the literature. 
Our primary objective was to characterize 3D cortical bone porosity changes in rabbit 
models of OP (OVX, GC, and OVX+GC) at the distal tibia using ex vivo micro-CT. Via 
correlative histomorphometry, we sought to test the hypothesis that cortical remodeling is 
elevated by these treatments relative to sham OVX controls (SHAM). Our secondary objective 
was to compare these changes with those caused by PTH, a known inducer of elevated intra-
cortical remodeling and porosity in the rabbit. Finally, we sought to characterize 3D trabecular 
bone changes in the proximal tibia across these groups to enable assessment of changes in 
different bony compartments and to facilitate comparison with the more extensive literature 
pertaining to trabecular bone. 
 
3.2. Materials and Methods 
3.21. Animals 
All animal work was approved by the University of Saskatchewan’s University Animal 
Care Committee and adhered to the Canadian Council on Animal Care (CCAC) guidelines for 
humane animal use. Thirty-five skeletally mature, 6-month old (3.7-3.9 kg), female New Zealand 
White rabbits were acquired from a commercial supplier, Charles River Laboratories (Quebec, 
Canada). Animals were housed individually in stainless steel rabbit racks in the University of 
Saskatchewan’s Health Sciences Laboratory Animal Services Unit, a CCAC accredited facility. 
Room temperature and humidity were controlled by a computerized system and the light cycle 
was maintained at 12:12 (12 hours of dark and 12 hours of light). Standard rabbit chow (Hi-Pro 
Feeds, Trouw Nutrition Canada Inc., Sherwood Park, Alberta, Canada) and reverse osmosis 
water through an automated watering system were provided ad libitum. Animals were 
acclimatized for a minimum of 7 days before any experimental procedures commenced. 
The rabbits were randomly divided into 5 groups of 7 animals each: SHAM, OVX, GC, 
OVX+GC, and PTH. The OVX and OVX+GC group underwent bilateral ovariectomy whereas 
the SHAM, GC, and PTH groups underwent bilateral sham OVX surgery. Fifty-six days (8 
weeks) post OVX/SHAM surgery (pre-dosing period), the GC groups (GC and OVX+GC) 
received Methylprednisolone Sodium Succinate (Pfizer, Kirkland, Quebec, Canada) by daily 
subcutaneous injection of 1.5 mg/kg for 4 weeks and the PTH group was dosed by daily 
subcutaneous injection for 4 weeks with human PTH (1-34) (Alfa Aesar, Ward Hill, MA, USA) 
at a concentration of 30 µg/kg (dosing period). The PTH dose used was intermediate to what has 
	 25 
been utilized in recent studies analyzing the effects of PTH dosing regimens (10 µg/kg/day vs. 40 
µg/kg/day) on rabbit cortical bone (106, 150). The GC dose used was an intermediate-to-high 
dose (0.5 mg/kg/day vs. 1.0 mg/kg/day vs. 2.0 mg/kg/day) based on a previous study analyzing 
OVX and OVX+GC OP models in the rabbit (152). SHAM and OVX received daily 
subcutaneous injections of 1 ml saline for the corresponding 4 week dosing period. Dose 
initiation at 8 weeks post-surgery was selected based upon previous studies that found 
conflicting BMD results in relation to time (4, 6, or 8 weeks) post OVX (152, 154, 162). Each 
animal was monitored daily at the time of injection, as well as weekly to assess weight. The bone 
labelling fluorochrome calcein (Sigma Aldrich, St. Louis, Missouri, USA) was administered by 
subcutaneous injection at a dose of 10 mg/kg on days 13 and 14 (label 1) and days 27 and 28 
(label 2; end-point) of the treatment period to facilitate dynamic histomorphometry. Animals 
were euthanized by intravenous injection of pentobarbital sodium (Euthanyl; Bimeda-MTC, 
Animal Health Inc, Cambridge, ON, Canada) at a dose of 0.4 ml/kg. Post-euthanasia, the right 
tibiae were removed and fixed in 10% formalin.  
 
3.22. Micro-CT Analysis 
The distal diaphysis and proximal epiphysis (Figure 3.1 C & A) were imaged with a 
SkyScan 1172 desktop micro-CT scanner (Bruker, Belgium) to assess cortical porosity and 
trabecular morphology, respectively. CTVol (version 2.3.2.0; Bruker, Belgium) was used to 
generate 3D volumetric renderings of cortical porosity and trabecular bone morphology. For 
cortical porosity analysis, a Volume of Interest (VOI) along 1 cm of the diaphysis, beginning 3 
cm proximal the distal end of the tibia, was scanned (Figure 3.1 C) at 75 kVp, 133 µA with 460 
ms exposure, 0.2º rotation step, 4-frame averaging, and a 0.5 mm aluminum filter. Resolution 
dependency of micro-CT analysis has long been recognized for both trabecular bone morphology 
(164) and cortical bone porosity (5). Here we chose a nominal resolution (voxel size) of 10 µm 
to specifically target cortical porosity on the scale of remodeling-related resorption 
spaces/osteons (~100 µm in rabbits (165)) with smaller spaces (including primary canals, mature 
secondary osteonal canals, osteocyte lacunae, and canaliculi) falling below the spatial resolution 
(Supplemental Figure 3.81). It should be noted that our resolution was higher (smaller voxel 
size) than that of micro-CT protocols previously applied to rabbit cortical bone (14-19 µm) (106, 
150, 154, 163). Important considerations for future study included that the 10 µm voxel size is 
similar in scale to that potentially available in vivo (33, 39) and the distal hind limb of the rabbit 
is well suited for live imaging with the animal in an upright position (151). We validated our 3D 
micro-CT outcomes through comparison with 2D histological measures of osteon size, 
confirming correlation between the approaches and similar distributions of values from each 
(Supplemental Figure 3.82). Finally, the distal tibia represents a region of elevated porosity 
relative to the mid-diaphysis (Supplemental Figure 3.83) consistent with observations of elevated 
remodeling distally in lower limb elements (166).  
For trabecular analysis, the proximal epiphysis of each tibia was scanned (Figure 3.1 A) 
at 75 kVp, 133 µA with 1080 ms exposure, 0.2° rotation step, 4-frame averaging, and a 0.5 mm 
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aluminum filter at a voxel size of 13 µm. The trabecular envelope within the entire epiphysis 
proximal to the growth plate was segmented as the VOI (Figure 3.1 A). The epiphyseal 
subchondral trabecular bone was targeted for both consistency with the existing literature (152, 
161) and the fact that little trabecular bone was present in the metaphyses of the rabbits (Figure 
3.1 A).   
Micro-CT data were reconstructed using the NRecon software package (Bruker, 
Belgium) and quantitative 3D analysis was conducted with CTAnalyser (CTAn; version 
1.16.4.1; Bruker, Belgium). To assess changes in cortical bone microarchitecture, Ct.Po (%) and 
mean canal diameter (Ca.Dm, µm) were measured after application of a standardized global 
threshold. Histograms representing the distribution of canal diameter sizes were produced to 
contrast patterns across the groups. For analysis of the trabecular VOIs, a standardized global 
threshold was again applied followed by 3D measurement of BV/TV (%), Tb.Th (mm), Tb.N 





Figure 3.1. Micro-Computed Tomography (micro-CT) image of rabbit tibia 
depicting regions of analyses. (A) Location of trabecular bone micro-CT analysis. 
Scan field height is 1 cm. Reconstructed micro-CT image of proximal tibia scan and 
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corresponding three-dimensional reconstructed image of isolated trabecular bone 
highlighted in yellow (right). (B) Location of histomorphometric analysis. Section is 
300 µm thick. Fluorescent confocal microscopy image of transverse section of 
cortical bone (right). (C) Location of cortical bone micro-CT analysis. Scan field 
height is 1 cm. Three-dimensional reconstructed image of cortical bone with cortical 
porosity highlighted in yellow (right). 
	
3.23. Dynamic Histomorphometry & Cortical Geometry 
Confocal microscopy images were acquired from a cortical cross-section placed 
immediately proximal to the micro-CT VOI (Figure 3.1 B). The sections were cut using a low 
speed sectioning saw with a diamond wafer blade and ground and polished to a thickness of 300 
µm (167). Mounted sections were subsequently imaged with a Leica (Leica Microsystems, 
Wetzlar, Germany) DMi8 confocal fluorescent microscope equipped with differential 
interference contrast microscopy (DIC) to capture fluorescent signals and cortical microstructure. 
2D mosaics of the DIC and fluorescent images were produced and analyzed using basic ImageJ 
(https://imagej.nih.gov/ij/) functions (unless otherwise described).  
Cross-sectional cortical geometry parameters, Ct.Ar (mm2), Ma.Ar (mm2), and Tt.Ar 
(mm2) were assessed and percent cortical and percent marrow area (%Ct.Ar, %Ma.Ar) were 
calculated relative to Tt.Ar. Cortical thickness (µm) was measured using the BoneJ (168) plugin 
for ImageJ. To complement the cortical geometry measures, estimates of maximal and minimal 
bending (second moments of area, Imax, Imin, mm4) as well as torsional stiffness (torsional 
section modulus, Zpol, mm3) were measured from the most proximal micro-CT cross-sectional 
image. These measures were performed on the micro-CT data as this modality enabled the 
impact of internal porosity/surface geometry to be better integrated into the measures. 
To evaluate the extent of active mineralization on bone surfaces, single and double 
labelled bone surfaces (sLS, dLS, respectively), and total bone surface (BS) were measured on 
the endosteal (Es) and periosteal (Ps) surfaces. Mineralizing surface per bone surface was 
calculated as (dLS+sLS/2)/BS on the endosteal (Es.MS/BS, %) and periosteal (Ps.MS/BS, %) 
surfaces. 
Intracortical remodeling activity was then counted manually as single labelled osteons 
(sL.On), double labelled osteons (dL.On), and resorption cavities (Rs.N), defined as non-
mineralizing pores characterized by eroded surfaces, no lamellar bone formation, and no calcein 
labelling. These parameters were normalized to Ct.Ar (sL.On/Ct.Ar, dL.On/Ct.Ar, and 
Rs.N/Ct.Ar, mm-2) and used to calculate a ratio of labelled osteons vs. resorption cavities 
((sL.On+dL.On)/Rs.N). In cross-sections where Rs.N was zero, a denominator of 1 was used to 
maximize the inclusion of data. Activation frequency was calculated as Ac.f = 
((sL.On+dL.On)/Ct.Ar)/σf (#/mm2/year), where σf, the osteon formation time, was calculated as 
W.Th/On.MAR (4). Wall thickness (W.Th, µm) reflects osteon wall thickness, the distance 
between osteon canal and cement line. This was measured from 50 randomly selected osteons for 
each animal within each transverse section using transmitted light microscopy at 20X 
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magnification. In sections with fewer than 50 osteons, all osteons present were measured. 
Osteonal mineral apposition rate (µm/day) was calculated as the inter-label distance, measured as 
the distance between two consecutive osteonal calcein labels, divided by the labeling period (14 
days). Osteonal mineral apposition rate was measured in 20 randomly selected dL.On within 
each transverse section. In sections with fewer than 20 dL.On, all osteons present were 
measured. Activation frequency was calculated from mean W.Th and On.MAR values for each 
animal and therefore, only rabbits with On.MAR values were included in the mean calculation of 
Ac.f. Finally, to provide a measure of overall remodeling activity that did not rely upon 
normalization to σf, we calculated active remodeling centers (a.Rm.Cr, mm-2) as the sum of 
resorption spaces and labelled osteons normalized to Ct.Ar: (sL.On+dL.On+Rs.N)/Ct.Ar. 
3.24. Statistical Analysis 
All statistical analyses were performed with SPSS version 26.0 (IBM, New York). The 
normality of all parameters was assessed by Shapiro-Wilk tests. Independent sample t tests were 
employed to evaluate animal weight percent change (testing difference from 0) across the entire 
experimental period (weeks 0-12) and also within the pre-dosing period (weeks 0-8) and the 
dosing period (weeks 8-12). When normally distributed for all groups, bone parameter data were 
assessed with One-way ANOVA (α = 0.05) and, when significant, post-hoc tests were used to 
compare all groups vs. SHAM. If non-normal distributions were detected for one or more groups, 
the non-parametric Kruskal-Wallis H tests (α = 0.05) with, when significant, post-hoc pairwise 
comparisons vs. SHAM using Dunn’s procedure (169) were carried out. To account for repeated 
pair-wise post-hoc tests, the alpha value was adjusted using Bonferroni’s method (170). For most 
measures, alpha and Confidence Intervals of the mean/median differences (SHAM – Treatment; 
hereafter just CI unless otherwise stated) were adjusted to account for the four pair-wise 
comparisons vs. SHAM resulting in α = 0.0125 (α = 0.05/4) and %CI = 98.75% (1- α). For 
comparisons lacking the two GC-dosed groups, the two pair-wise comparisons employed α = 
0.025 and %CI = 97.5%. To calculate the CIs, additional independent t tests for the normal data 
and Hodges-Lehmann tests for the non-normal data were employed. Instances where p > α but 
CIs did not straddle zero were flagged in the tables. Finally, fold changes relative to SHAM 
(Treatment / SHAM) were calculated for all parameters.   
	
3.3. Results  
3.31. Animal Weight 
Statistics for weight and % weight change are summarized in Table 3.1 and depicted in 
Figure 2. SHAM, OVX, and OVX+GC gained weight during the 8-week pre-dosing period. 
While p > α for GC and PTH, the 95% CI of the percent change suggests weight gain in PTH 
should not be ruled out. During the 4-week dosing period SHAM and OVX again gained weight 
while GC, OVX+GC, and PTH all lost weight. Considering the entire 12-week experimental 





Figure 3.2. Analyses of mean changes in body weight in rabbit groups over 
experimental time period (0-3 months). Data are presented by boxplots with 
individual rabbits plotted as solid circles and outliers plotted as open circles. N=7. 
*Indicates p < 0.05 compared to 0 (independent sample t test). SHAM = control. 
OVX = Ovariectomy. GC = Glucocorticoid. OVX+GC = Ovariectomy & 


























Table 3.1. Rabbit Weight Analyses 
 SHAM OVX GC OVX+GC PTH 
Parameter Mean ± SD vs. 0  p 95% CI Mean ± SD vs. 0  p 95% CI  Mean ± SD vs. 0  p 95% CI    Mean ± SD vs. 0  p  95% CI     Mean ± SD vs. 0  p  95% CI 
% Weight Change Pre-
Dosing Period  10.37 ± 7.04  0.008* 3.86 – 16.87 12.80 ± 5.02 0.001* 8.16 – 17.45 -0.27 ± 5.19 0.894 -5.07 – 4.53 6.63 ±7.11 0.049* 0.05 – 13.20 7.80 ± 8.58 0.053 -0.13 – 15.74 
% Weight Change 
Dosing Period 3.60 ± 1.23 <0.001* 2.46 – 4.74 4.86 ± 3.15 0.006*   1.95 – 7.77 -9.44 ± 6.33 0.008* -15.29 - -3.58 -10.23 ± 7.45 0.011* -17.13 - -3.34 -5.69 ± 4.22 0.012* -9.59 - -1.78 
% Weight Change 
Experimental Period 14.33 ± 7.24 0.002* 7.64 – 21.02 18.18 ± 3.21 <0.001*    15.21 – 21.15 -9.56 ± 9.49 0.037* -18.34 - -0.78 -4.04 ± 12.62 0.430 -15.71 – 7.64 1.75 ± 10.46 0.674 -7.92 – 11.42 
	
Values are reported as mean ± standard deviation. N=7. Independent sample t tests were employed. Significance level for t tests was α = 0.05 
for comparison to 0. 95% confidence intervals (CI) of the mean are reported. SHAM = control. OVX = Ovariectomy. GC = Glucocorticoid. 
OVX+GC = Ovariectomy & Glucocorticoid. PTH = Parathyroid Hormone.  
	
 31	
3.32. Cortical Porosity 
Representative micro-CT 2D cross-sectional images and 3D renders of the VOIs are 
provided in Figure 3.3 A. Cortical pores appeared to be non-uniform and clustered within 
portions of the mid-cortex. Measurements of Ct.Po and Ca.Dm are summarized in Table 3.2 and 
Figure 3.3 B-C. Evidence of increased Ct.Po was observed for all groups. For OVX, OVX+GC, 
and PTH, p < α, while GC exhibited a 4.6-fold increase and the CI was strongly offset from zero. 
Similar fold-change increases and CI ranges were observed across all groups for Ca.Dm (Figure 
3.3 C), although p < α  was only observed for OVX+GC and PTH. The distributions of Ca.Dm 
values (Figure 3.3 D) reflected the relatively low proportion of large resorption-space sized pores 
in SHAM, although this group did exhibit a peak in distribution of values around the expected 
(100 µm) osteon/resorption space diameter for rabbits. A similar peak dominated the 
distributions for OVX and PTH. The two GC dosed groups (GC and OVX+GC) exhibited a 





Figure 3.3. Micro-CT based analyses of cortical bone in rabbit tibiae. (A) 
Representative two-dimensional micro-CT cross sectional images of cortical bone in 
distal rabbit tibiae in various treatment groups with corresponding three-dimensional 
renders of volume of interest (below). Regions of cortical porosity at the level of 
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vascular canals are highlighted in yellow. Scale bar = 1 mm. (B) Cortical Porosity 
(Ct.Po) analysis in rabbit tibiae. Data are presented by boxplot with individual rabbits 
plotted as solid circles and outliers plotted as open circles. N=7. *Indicates p < 
0.0125 compared to SHAM (Kruskal-Wallis with post-hoc Dunn’s test). (C) Canal 
Diameter (Ca.Dm) analysis in rabbit tibiae. Data are presented by boxplot with 
individual rabbits plotted as solid circles and outliers plotted as open circles. N=7. 
*Indicates p < 0.0125 compared to SHAM (One-way ANOVA with post-hoc 
Bonferroni test). (D) Histograms depicting distributions of canal diameters in rabbit 
tibiae for each group. SHAM = control. OVX = Ovariectomy. GC= Glucocorticoid. 




Table 3.2. Micro-CT Cortical Bone Parameters 
  SHAM OVX GC OVX+GC PTH 









  Mean ± SD 








  Change 




















Ct.Po (%) <0.001*   0.13 ± 0.04 (0.13) 
0.75 ± 0.37 
(0.69) 0.007* 
-0.56 
(-1.04 - -0.20) 5.8 
0.60 ± 0.73 
(0.39) 0.064 
-0.24 
(-2.09 - -0.06)a 4.6 
1.38 ± 1.12 
(0.82)  0.001* 
-0.69 
(-3.49 - -0.57) 10.6 
3.75 ± 2.24 
(3.42) <0.001* 
-3.29 
(-6.78 - -0.92) 
28. 
8 
Ca.Dm (µm) 0.003* 70.00 ± 27.40 99.00 ± 12.80 0.050 -28.84 (-62.37 – 4.69) 1.4    107.00 ± 24.10 0.015 
-36.41 
(-76.90 – 4.09) 1.5 133.00 ± 42.30  <0.001* 
-62.59 
(-118.47 - -6.71) 1.9    108.00 ± 14.80 0.012* 
-37.68 
(-72.23 - -3.12) 1.5 
 
Values are reported as mean ± standard deviation. Median values are also reported for those parameters where at least one group was not normally 
distributed. N=7. One-Way ANOVA with post-hoc Bonferroni tests were employed for normal data. Kruskal Wallis test with post-hoc Dunn’s tests 
were employed for non-normal data. Significance level for the overall tests was α = 0.05 with the post-hoc tests adjusted for multiple comparisons 
vs. SHAM (α = 0.0125). Mean differences and 98.75% CI of the mean differences are reported from independent t tests for normal data. Median 
differences and 98.75% CI of the median differences are reported from Hodges-Lehmann tests for non-normal data. aIndicates instances of 
disagreement between CIs and p values. Fold changes are reported relative to SHAM. Ct.Po = Cortical Porosity. Ca.Dm = Canal Diameter. SHAM 




Figure 3.4. (A) Differential Interference Contrast (DIC) and fluorescent confocal 
microscopy images of transverse sections of rabbit tibiae in various treatment groups. 
Green fluorescent signal from calcein depicts areas of active bone formation. Absent 
signals from GC treated rabbits are due to inhibition of osteoblastic mediated bone 
formation by GC treatment. Scale bar = 1 mm. SHAM = control. OVX = 
Ovariectomy. GC = Glucocorticoid. OVX+GC = Ovariectomy & Glucocorticoid. 
PTH = Parathyroid Hormone. (B-D) Representative confocal microscopy images of 
(B) single labelled osteon, (C) double labelled osteon, and (D) resorption cavity. 
Scale bar = 50 µm. (E) Confocal microscopy image of PTH endosteal surface in 
transverse section. Note the trabecularized appearance of bone formed on the 
endosteal surface, a feature typical of woven bone. Scale bar = 150 µm. (F) 
Corresponding three-dimensional reconstructed micro-CT image of PTH endosteal 
surface. (G) Confocal microscopy image of GC endosteal surface in transverse 
section. Note scalloped appearance of endosteal bone. Scale bar = 150 µm. (H) 
Corresponding three-dimensional reconstructed micro-CT image of GC endosteal 
surface. 
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3.33. Cortical Bone Geometry 
Representative DIC images are provided in Figure 3.4 and all cross-sectional geometry 
measures are summarized in Figure 3.5. It was evident from these images, as well as the 2D 
histological and 3D micro-CT images (Figure 3.4 G and Figure 3.3 A, respectively), that net 
resorption occurred at the endosteal surfaces of the two GC-dosed groups (GC and OVX+GC) 
with large trench-like packets of bone being removed (Figure 3.4 G). Quantitatively (Table 3.3), 
fold changes were generally subtle and the qualitative observations noted above were not 





Figure 3.5. (A-I) Cortical bone geometry analyses in rabbit tibiae. Data are presented by boxplots with individual rabbits plotted as 
solid circles and outliers plotted as open circles. N=7. *Indicates p < 0.0125 compared with SHAM (One-way ANOVA with post-
hoc Bonferroni test). Ct.Ar = Cortical Area. Ma.Ar = Marrow Area. Tt.Ar = Total Area. Ct.Th = Cortical Thickness. Imax = 
Maximum second moment of area. Imin = Minimum second moment of area. Zpol = torsional section modulus. SHAM = control. 




Table 3.3. Cortical Bone Geometry Parameters 
  SHAM OVX GC OVX+GC PTH 






   Fold 















Tt.Ar (mm2) 0.059 35.20 ± 1.86 35.10 ± 3.91 - 0.13 (-4.67 – 4.93) 1.0 31.30 ± 1.28 - 
3.85 
(1.34 – 6.36)a 0.9 34.60 ± 3.33 - 
0.62 
(-3.62 – 4.85) 1.0 33.80 ± 1.62 - 
1.38 
(-1.36 – 4.12) 1.0 
Ct.Ar (mm2) 0.001* 24.40 ± 1.23 23.10 ± 2.93 0.100 1.40 (-2.13 – 4.92) 0.9 20.90 ± 1.52 0.001* 
3.52 
(1.35 – 5.69) 0.9 22.00 ± 1.59 0.016 
2.42 
(0.19 – 4.65)a 0.9 25.10 ± 0.91 0.100 
-6.65 
(-2.34 – 1.05) 1.0 
Ma.Ar (mm2) 0.007* 10.70 ± 1.72 12.00 ± 1.83 0.100 -1.26 (-4.05 – 1.53) 1.1 10.40 ± 1.42 0.100 
0.33 
(-2.14 – 2.80) 1.0 12.50 ± 2.46 0.086 
-1.80 
(-5.13 – 1.53) 1.2 8.72 ± 1.90 0.055 
2.02 
(-0.82 – 4.87) 0.8 
% Ct.Ar (%) <0.001* 69.50 ± 3.83 65.70 ± 3.49 0.091 3.82 (-1.93 – 9.57) 0.9 66.80 ± 4.19 0.100 
2.78 
(-3.51 – 9.08) 1.0 63.90 ± 4.25 0.015 
5.63 
(-0.72 – 11.97) 0.9 74.40 ± 4.59 0.036 
-4.80 
(-11.42 – 1.83) 1.1 
% Ma.Ar (%) <0.001* 30.40 ± 3.83 34.30 ± 3.49 0.091 -3.82 (-9.57 – 1.93) 1.1 33.20 ± 4.19 0.100 
-2.78 
(-9.08 – 3.51) 1.1 36.10 ± 4.25 0.015 
-5.63 
(-11.97 – 0.72) 1.2 25.60 ± 4.59 0.036 
4.80 
(-1.83 – 11.42) 0.8 
Ct.Th (µm) 0.019* 1448.63 ± 88.94 1338.49 ± 144.44 0.100 110.14 (-78.00 – 298.27) 0.9  1295.81 ± 161.98 0.070 
152.82 
(-51.38 – 357.01) 0.9    1247.01 ± 176.85 0.019 
201.61 
(-17.94 – 421.16) 0.9 1504.26 ± 172.80 0.100 
-55.63 
(-270.88 – 159.61) 1.0 
Imin (mm4) 0.030* 59.79 ± 5.82 59.88 ± 15.62 0.100 
-0.09 
(-18.58 – 18.40) 1.0 44.92 ± 5.40 0.007* 
14.88 
(6.06 – 23.69) 0.8 50.10 ± 10.54 0.070 
9.69 
(-3.67 – 23.05) 0.8 54.22 ± 6.91 0.100 
5.57 
(-4.46 – 15.60) 0.9 
Imax (mm4) 0.039* 125.35 ± 15.98 132.22 ± 36.29 0.100 
-6.87 
(-50.85 – 37.12) 1.1 97.16 ± 6.08 0.017 
28.19 
(9.22 – 47.15)a 0.8   112.65 ± 21.08 0.100 
12.70  
(-16.64 – 42.04) 0.9 119.14 ± 11.13 0.100 
6.21 
(-15.39 – 27.81) 1.0 
Zpol (mm3) 0.019* 43.40 ± 3.08 42.42 ± 8.07 0.100 
0.98 
(-8.59 – 10.56) 1.0 35.45 ± 2.26 0.003* 
7.95 
(3.71 – 12.18) 0.8 37.86 ± 4.29 0.034 
5.53 
(-0.32 – 11.39) 0.9 40.65 ± 3.20 0.100 
2.75 
(-2.17 – 7.67) 0.9 
 
Values are reported as mean ± standard deviation. N=7, except for On.MAR and Ac.f measures for OVX (N=5) and SHAM (N=3). One-Way ANOVA 
with post-hoc Bonferroni tests were employed for normal data. Significance level for the overall tests was set at α = 0.05 with the post-hoc tests 
adjusted for multiple comparisons vs. SHAM (α = 0.0125). Mean differences and 98.75% confidence intervals (CI) of the mean differences are 
reported from independent t tests. aIndicates instances of disagreement between CIs and p values. Fold changes are reported relative to SHAM. Tt.Ar = 
Total Area. Ct.Ar = Cortical Area. Ct.Th = Cortical Thickness. Ma.Ar = Marrow Area. Imin = Minimum second moment of area. Imax = Maximum 
second moment of area. Zpol = Torsional section modulus. Ma.Ar = Marrow Area. SHAM = control. OVX = Ovariectomy. GC = Glucocorticoid. 
OVX+GC = Ovariectomy & Glucocorticoid. PTH = Parathyroid Hormone. 
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3.34. Cortical Bone Histomorphometry 
The calcein labels revealed active bone formation on the periosteal and endosteal surfaces 
as well as intra-cortical bone formation within actively forming osteons (Figures 3.4 and 3.6, 
Table 3.4). Formation was most pronounced in the PTH group, particularly at the endosteal 
surface and intra-cortically (reflected qualitatively in many geometry parameters in Figure 3.5). 
Conversely, the GC and OVX+GC groups exhibited reduced evidence of labelled bone 
formation on all surfaces (Figure 3.4 A). Due to the lack of formation, measures relying upon 
calcein labels were not assessable for GC and OVX+GC and were reported as no data (ND) in 
Table 3.4. Bone formation at both surfaces, Es.MS/BS and Ps.MS/BS, was increased in the PTH 
group. Endosteal bone formation in PTH had a distinct pattern that included well organized 
lamellar bone in places but also disorganized plates with a crude trabecular-like pattern 
reminiscent of woven bone in others (Figure 3.4 E & F). Periosteal MS/BS was highly variable 
with large outliers detected for SHAM and OVX.  
Evidence of elevated remodeling was most dramatically and consistently observed in 
PTH with p < α for sL.On/Ct.Ar, dL.On/Ct.Ar, Rs.N/Ct.Ar, Ac.f, and a.Rm.Cr/Ct.Ar. The OVX  
group exhibited a similar but less pronounced (fold changes approximately half those of PTH) 
pattern for these parameters; although p < α was only detected for a.Rm.Cr/Ct.Ar, CIs with 
values largely distributed to one side of zero and with relatively large extremes caution against 
disregarding potential changes in the other parameters. For the glucocorticoid groups, 
Rs.N/Ct.Ar was elevated approximately 10- and 18-fold for GC and OVX+GC. Although only 
the latter had p < α, the large fold change and distribution of the CI for GC again caution against 
disregarding a potential effect. The ratio of labelled osteons to resorption cavities (sL.On + 
dL.On)/Rs.N was 0.1 and 0.4 of that for SHAM for OVX+GC and GC, respectively, with the 





Figure 3.6. (A-J) Histomorphometric analyses of transverse cortical bone sections in 
rabbit tibiae. Data are presented by boxplots with individual rabbits plotted as solid 
circles and outliers plotted as open circles. N=7 except for On.MAR and Ac.f 
measures for OVX (N=5) and SHAM (N=3). *Indicates p < 0.0125 compared to 
SHAM unless otherwise stated (Kruskal-Wallis with post-hoc Dunn’s test for 
dL.On/Ct.Ar, sL.On/Ct.Ar, Rs.N/Ct.Ar, a.Rm.Cr/Ct.Ar, and W.Th). For On.MAR, 
Ac.f, PS.MS/BS, and Es.MS/BS, *indicates p < 0.025 (One-way ANOVA with post 
hoc Bonferroni test for Es.MS/BS, On.MAR, and Ac.f, Kruskal-Wallis with post-hoc 
Dunn’s test for PS.MS/BS). sL.On = Single Labelled Osteon. dL.On = Double 
Labelled Osteon. Rs.N = Resorption Cavity Number. a.Rm.Cr = Active Remodeling 
Centers. Ct.Ar = Cortical Area. W.Th = Wall Thickness. On.MAR = Osteonal 
Mineral Apposition Rate. Ac.f = Activation Frequency. Es = Endosteal. Ps = 
Periosteal. MS/BS = Mineralizing Surface per Bone Surface. SHAM = control. OVX 
= Ovariectomy. GC = Glucocorticoid. OVX+GC = Ovariectomy & Glucocorticoid. 
PTH = Parathyroid Hormone. 
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Table 3.4. Cortical Bone Histomorphometric Parameters 
  SHAM OVX GC OVX+GC PTH 




  Fold    
 Change 
  Mean ± SD 






     Fold 




 Fold   
 Change 
  Mean ± SD 









sL.On/Ct.Ar (mm-2) 0.001* 0.21 ± 0.16 (0.16) 
0.99 ± 0.49 
(0.99) 0.020 
0.80 
(0.13 – 1.42)a 4.1 
0.44 ± 0.57 
(0.05) 0.734 
-0.03 
(-0.31 – 1.12) 2.1 
  0.26 ± 0.22 
   (0.32) 0.855 
0.02 
(-0.28 – 0.42) 1.2 
1.80 ± 0.91 
(1.73) 0.001* 
1.59 
(0.34 – 2.92) 8.4 
dL.On/Ct.Ar (mm-2) <0.001* 0.04 ± 0.05 (0.00) 
0.62 ± 0.41 
(0.81) 0.031 
0.78 
(0.00 – 0.95) 15.4 
0.01 ± 0.02 
(0.00) 0.471 
0.00 
(-0.08 – 0.00) 0.2 
  0.01 ± 0.02 
   (0.00)     0.454 
0.00 
(-0.08 – 0.00) 0.2 
1.05 ± 0.55 
(0.91) 0.002* 
0.91 
(0.42 – 1.81) 26.3 
Rs.N/Ct.Ar (mm-2) <0.001* 0.05 ± 0.05 (0.04) 
0.49 ± 0.40 
(0.27) 0.015 
0.23 
(0.07 – 1.00)a 10.7 
0.47 ± 0.41 
(0.27) 0.016 
0.23 
(0.11 – 1.22)a 10.1 
  0.80 ± 0.50 
   (0.65)   <0.001* 
0.61 
(0.19 – 1.52) 17.5 
1.03 ± 0.41 
(1.10) <0.001* 
1.01 
(0.37 – 1.64) 22.4 
a.Rm.Cr/Ct.Ar (mm-2) <0.001* 0.30 ± 0.17 (0.31) 
2.10 ± 1.15 
(2.78) 0.002* 
2.43 
(0.23 – 2.92) 7.0 
0.92 ± 0.81 
(0.62) 0.144 
0.38 
(-0.13 – 2.16) 3.1 
1.07 ± 0.66 
(0.91) 0.042 
0.60 
(0.04 – 1.86)a 3.6 
3.87 ± 1.59 
(4.00) <0.001* 
3.68 
(1.51 – 5.60) 12.9 
(sL.On + dL.On)/ 
Rs.N 
0.003* 4.40 ± 3.02 (4.00) 
4.97 ± 4.39 
(3.00) 0.990 
0.33 
(-5.80 – 8.33) 1.1 
1.66 ± 2.58 
(0.09) 0.025 
-2.33 
(-7.00 – 2.50) 0.4 
0.37 ± 0.29 
(0.37) 0.002* 
-3.63 
(-8.62 - -0.63) 0.1 
2.93 ± 1.15 
(2.90) 0.686 
-1.38 
(-6.05 – 2.22) 0.7 
W.Th (µm) 0.093 44.49 ± 0.59 (44.15) 
44.56 ± 1.57 
(44.19) - 
-0.04 
(-2.36 – 2.21) 1.0 
45.63 ± 2.89 
(45.71) - 
-1.42 
(-4.51 – 4.04) 1.0 
   46.34 ± 1.37 
(46.39) - 
  -1.34 
(-3.94 – 0.19) 1.0 
45.11 ± 1.29 
(45.08) 0.961 
-0.43 
(-2.54 – 1.15) 1.0 
On.MAR (µm/day) 0.013* 1.77 ± 0.21 2.35 ± 0.40 0.015* -0.58
 
(-1.34 – 0.18)a 1.3 ND ND ND ND ND ND ND ND 2.45 ± 0.19 0.005* 
-0.68 
(-1.06 - -0.30) 1.4 
Ac.f (#/mm2/yr) 0.012* 4.04 ± 1.89 32.43 ± 16.28 0.102 -28.39 (-57.31 – 0.53) 8.0 ND ND ND ND ND ND ND ND 57. 54 ± 27.98     0.004* 
-53.49 
(-99.54 - -7.45) 14.2 
Es.MS/BS (%) <0.001* 23.65 ± 13.01 27.39 ± 23.26 0.100 61.19 (-29.52 – 22.06) 1.2 ND ND ND ND ND ND ND ND 84.84 ± 13.17 <0.001* 
57.46 
(-79.11 - -43.27) 3.6 
Ps.MS/BS (%) 0.027* 18.44 ± 15.34 (13.75) 
21.34 ± 26.67 
(7.98) 0.100 
-2.75 
(-27.40 – 37.69) 1.2 ND ND ND ND ND ND ND ND 
48.58 ± 8.77 
(47.35) 0.020* 
-33.14 
(-47.51 - -9.35) 2.6 
	
Values are reported as mean ± standard deviation. Median values are also reported for those parameters where at least one group was not normally 
distributed. N=7. One-Way ANOVA with post-hoc Bonferroni tests were employed for normal data. Kruskal-Wallis tests with post-hoc Dunn’s 
tests were employed for non-normal data.  Significance level for the overall tests was α = 0.05 with the post-hoc tests adjusted for multiple 
comparisons vs. SHAM (α = 0.0125). GC and OVX+GC were not analyzed for On.MAR, Ac.f, Es.MS/BS, and Ps.MS/BS due to a lack of 
detected labels and thus the significance level was adjusted for associated post-hoc tests (α = 0.025). Mean differences and 98.75% (α = 0.0125) or 
97.5% (α = 0.025) confidence intervals (CI) of the mean differences are reported from independent t tests for normal data. Median differences and 
98.75% (α = 0.0125) or 97.5% (α = 0.025) CI of the median differences are reported from Hodges-Lehmann tests for non-normal data. aIndicates 
instances of disagreement between CIs and p values. Fold changes are reported relative to SHAM. sL.On = Single Labelled Osteon. dL.On = 
Double Labelled Osteon. Rs.N = Resorption Cavity Number. a.Rm.Cr = Active Remodeling Centers. Ct.Ar = Cortical Area. W.Th = Wall 
Thickness. On.MAR = Osteonal Mineral Apposition Rate. Ac.f = Activation Frequency. Es= Endosteal. Ps = Periosteal. MS/BS = Mineralizing 
Surface per Bone Surface. SHAM = control. OVX = Ovariectomy. GC = Glucocorticoid. OVX+GC = Ovariectomy & Glucocorticoid. PTH = 
Parathyroid Hormone. ND = No Data. 
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3.35. Trabecular Bone Micro-CT 
Figure 3.7 A presents 3D renders of a portion of the VOI used for analysis of trabecular 
morphology. Overall, although fold changes were more subtle than many of the cortical 
parameters, a pattern of loss was observed for OVX, GC, and OVX+GC groups, while the 
opposite was observed for PTH (Table 3.5 and Figure 3.7 B-E). The reduction in BV/TV had p < 
α for both glucocorticoid groups, while OVX exhibited a similar fold change and a CI including 
zero but values offset to one side. Conversely, PTH exhibited the opposite pattern with the 
largest fold change (1.2) and strongly offset CI. Changes in Tb.N consistently supported the 
overall patterns of change with p < α for all groups. A predictable concomitant change in Tb.Sp 
was, generally, supported by the fold changes and CIs while Tb.Th had the smallest fold changes 
and CIs most evenly distributed about zero indicating the stability of this parameter across the 





Figure 3.7. Micro-CT based analyses of trabecular bone in rabbit tibiae. (A) Three-dimensional reconstructed images of epiphyseal 
subchondral trabecular bone structure in rabbit tibiae of various treatment groups. Regions of trabecular bone are highlighted in 
yellow. Scale bar = 1 mm. (B-E) Three-dimensional trabecular bone analyses in rabbit tibiae. Data are presented by boxplots with 
individual rabbits plotted as solid circles and individual outliers plotted as open circles. N=7. *Indicates p < 0.0125 compared to 
SHAM (One-Way ANOVA with post-hoc Bonferroni test for Tb.Th and BV/TV, Kruskal-Wallis with post-hoc Dunn’s test for Tb.Sp 
and Tb.N). BV/TV = Bone Volume/Tissue Volume. Tb.Th = Trabecular Thickness. Tb.N = Trabecular Number. Tb.Sp = Trabecular 










Table 3.5. Micro-CT Trabecular Bone Parameters 
  SHAM OVX GC OVX+GC PTH 




   Fold 
   Change 
      Mean ± SD 









  Mean ± SD 



















BV/TV (%) <0.001* 40.73 ± 3.97 (37.93) 
34.94 ± 3.57 
(35.49) 0.112 
-4.90 
(-12.00 – 0.87) 0.9 
  31.01 ± 5.33 
(33.48) 0.006* 
-8.87 
 (-17.42 - -2.33) 0.8 
32.45 ± 1.54 
(32.77) 0.004* 
-7.77 
(-14.13 - -4.10) 0.8 
49.60 ± 5.62 
(49.36) 0.220 
8.28 
(-0.84 – 17.68) 1.2 
Tb.Th (mm) 0.065 0.20 ± 0.01 (0.20) 
0.20 ± 0.01 
(0.20) - 
0.00 
(-0.02 – 0.01) 1.0 
         0.19 ± 0.02 
(0.19) - 
-0.01 
(-0.05 – 0.01) 0.9 
0.20 ± 0.02 
(0.21) - 
0.00 
(-0.03 – 0.02) 1.0 
  0.21 ± 0.01 
   (0.21) - 
0.01 
(-0.01 – 0.02) 1.0 
Tb.Sp (mm) 0.018* 0.44 ± 0.06   0.53 ± 0.10  0.015 -0.09 (-0.22 – 0.04) 1.2    0.52 ± 0.05 0.031 
-0.08 
(-0.16 – 0.00) 1.2 0.52 ± 0.04 0.039 
-0.08 
(-0.15 – 0.00) 1.2 0.44 ± 0.07 0.100 
0.01 
(-0.09 – 0.10) 1.0 
Tb.N (mm-1) <0.001* 2.02 ± 0.17 1.75 ± 0.17  0.012* 0.26 (0.00 – 0.53) 0.9   1.65 ± 0.16 0.001* 
0.37 
(0.11 – 0.63) 0.8 1.65 ± 0.12 0.001* 
0.37 
(0.14 – 0.60) 0.8  2.36 ± 0.27 0.002* 
-0.34 
(-0.69 – 0.01) 1.2 
 
Values are reported as mean ± standard deviation. Median values are also reported for those parameters where at least one group was not normally 
distributed. N=7. One-Way ANOVA with post-hoc Bonferroni tests were employed for normal data. Kruskal Wallis test with post-hoc Dunn’s tests 
were employed for non-normal data. Significance level for the overall tests was α = 0.05 with the post-hoc tests adjusted for multiple comparisons 
vs. SHAM (α = 0.0125). Mean differences and 98.75% confidence intervals (CI) of the mean differences are reported from independent t tests for 
normal data. Median differences and 98.75% CI of the median differences are reported from Hodges-Lehmann tests for non-normal data. aIndicates 
instances of disagreement between CIs and p values.  Fold changes are reported relative to SHAM. BV/TV = Bone Volume/Tissue Volume. Tb.Th 
= Trabecular Thickness. Tb.N = Trabecular Number. Tb.Sp = Trabecular Separation. SHAM = control. OVX = Ovariectomy. GC = 




In general, the animals tolerated the OVX/sham surgeries well and weight gain was 
observed in three of the groups during the pre-dosing period (SHAM, OVX, and OVX+GC) and 
suggested by the data for the fourth (GC). Glucocorticoid dosing was not as well tolerated by the 
animals and weight loss was observed during the dosing period, an observation consistent with 
past studies for GC (159) and OVX+GC (163). Three of the GC rabbits had a more extreme 
reaction to treatment exhibiting hair textural changes. Notably, the 1.5 mg/kg/day dose we 
administered is moderate to high in the context of existing literature and 2 mg/kg/day has been 
reported as lethal (152). Further, administering lower doses (1 mg/kg/day) over longer lengths of 
time (six weeks) had also resulted in the premature death of one animal (163). As such, 
increasing GC dose or the length of dosing to possibly induce larger scale differences in cortical 
bone parameters may not be feasible in terms of animal welfare. Parathyroid hormone dosing 
was well tolerated by the animals. While they exhibited weight loss over the dosing period, it 
was less pronounced than that observed in the GC-dosed groups. Hirano and colleagues (71) 
found a similar decrease in weight after dosing rabbits with a comparatively higher dose of PTH 
at 40 µg/kg/5 days a week for 20 weeks. 
The characterization of cortical porosity in the OP models and PTH was our primary 
objective and evidence of elevations were detected in all groups. Comparative data are limited as 
cortical porosity is only sparsely reported in the literature for rabbit OP models. In a recent 
report, Chandler and colleagues (163) observed no difference in Ct.Po at the femoral mid-
diaphysis between SHAM (0.50%) and OVX (0.43%) groups at 18 weeks post-surgery, while 
their OVX+GC group (dosed for 12 weeks commencing 6 weeks after OVX) had elevated Ct.Po 
(9.75%). It is unclear what underpins their lack of a difference for OVX compared with our 
study. It could relate to the different skeletal elements studied (femur vs. tibia), relative location 
of the VOI (mid-shaft vs. distal shaft), the larger (15 µm) voxel size used, and/or Chandler and 
colleagues’ longer duration post-surgery. Regarding the latter, their longer post-surgery phase for 
OVX, at 18 weeks vs. our 12 weeks, may have enabled more time for cortical remodeling to 
reach steady state (see discussion of Ac.f below). The PTH group had the most pronounced 
difference in Ct.Po, a result consistent with recent reports. Yamane and colleagues (150) reported 
a Ct.Po of 3.62% in rabbit tibiae after treatment with 40 µg/kg/day of PTH for 4 weeks, assessed 
using micro-CT at a 19.1 µm voxel size, while Zebaze and colleagues (106) reported a higher 
Ct.Po of 8.7% in rabbit femora using the same dosing regimen and imaging at 15 µm voxel size. 
Across all groups, qualitative inspection of the images suggested the cortical pores did 
not appear to be randomly distributed rather, they were frequently clustered in the mid-cortex. 
The reason underpinning this is unclear although, it may be linked to developmental features and 
the localized age of the tissue. In rats, central bands or “islands” of calcified cartilage have been 
observed indicating remnants of developmental tissues in the mid-cortex (171, 172). It is unclear 
if this was the case in our rabbits, although the central cortex had distinctly complex 
microarchitecture when compared with more organized lamellar bone, which was particularly 
evident at the periosteal surface. Mid-cortical porosity in PTH contrasts with observations by 
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Zebaze and colleagues (106) and Hirano and colleagues (105) who reported increased porosity 
primarily adjacent to the marrow cavity in the proximal femur and tibial midshaft of rabbits, 
respectively. It is unclear if these endosteal pores reported by others may be related to the 
endosteal bone formation we observed.   
 Canal diameter values for SHAM were slightly lower (mean of 70 µm) than anticipated 
for remodeling-related resorption spaces in rabbits. This 3D micro-CT measure, however, 
includes all resolved pores ranging in size from the maximal diameter of cutting-cones, down 
through the contracting diameter of the closing-cones and, ultimately, approaching the normal 
scale of mature quiescent canals. The latter were not resolved by our micro-CT protocol 
(Supplemental Figure 3.81). The distribution of Ca.Dm (Figure 3.3 D) for SHAM did reveal a 
peak in values at the expected 100 µm size for secondary osteons/resorption spaces in rabbits. 
The distributions of Ca.Dm were very similar for OVX and PTH and their modal values (~100 
µm) corresponded closely with the peak in SHAM. This suggests that the maximal diameters of 
the resorption spaces created in these groups are similar and of a scale consistent with past 
reports of normal secondary osteon size in rabbits. Conversely, the GC-dosed groups exhibited 
distributions skewed toward larger Ca.Dm, suggesting larger initial resorption spaces or the 
coalescence of spaces in the cortex. Two-dimensional data (Supplemental Figure 3.82) 
corroborate that pore sizes were increased in the GC-dosed groups but also in PTH. Zebaze and 
colleagues (106) have suggested PTH produces larger pores by enlarging existing canals which 
then coalesce, evidenced by micro-CT analysis.  
Our secondary objective was to test the hypothesis that elevations in cortical porosity are 
associated with increased remodeling rates in these rabbit OP models, which we found to be 
increased in all groups relative to SHAM. Activation frequency represents the most direct 
measure of the rate of remodeling as it is a measure of the birth rate of new BMUs. That said, 
this measure presented several challenges for our study. First, both GC-dosed groups exhibited 
little sign of bone formation, rendering measures relying upon the labelled structures 
unassessable for these groups. This was consistent with the primary mechanism of GC-induced 
bone loss via osteoblast suppression (173). The low numbers of double-labelled osteons in 
SHAM and OVX, including their absence in some animals, further complicated the assessment 
of Ac.f. which requires labelled osteons in its numerator and osteon formation time (σf = 
W.Th/On.MAR) in its denominator. This reduced the number of animals available for the 
comparisons of this parameter, diminishing statistical power and thus, the generalizability of the 
results should be interpreted with caution. Finally, a key basis of this estimation of BMU birth 
rate is the assumption of a steady state where the same number of BMUs (generally quantified as 
labelled osteons) are being “born” and “dying”. Given that we expected elevation in remodeling 
rate for the OP models and that it has been previously demonstrated for PTH, this assumption is 
dubious in our case. Further, equal birth and death rates for duration of the newly established σf 
is needed to reach a new steady state after experimental perturbation (4). Osteon formation time 
assessed in our study (based upon mean W.Th and On.MAR reported in Table 4) was 
approximately 25, 19, and 18 days for SHAM, OVX, and PTH, respectively. There simply was 
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not enough time in our 28-day dosing period, with calcein labels first administered at the 
midpoint, for a new steady state to have occurred for PTH and GC. Whether or not the OVX 
group had reached a new steady state is less clear, but it is more plausible since the first calcein 
label was administered 69 and 70 days after surgery. Despite these limitations, we have reported 
Ac.f here to facilitate comparison with existing studies (which may also not meet the underlying 
assumptions) and, in the case of OVX rabbits (8-fold increase relative to SHAM with the caveat 
that p > α), provide novel, albeit limited, data to the literature. Our Ac.f value for PTH was 14-
fold higher than SHAM, a result that aligns well with a previous study of rabbits dosed with 40 
µg/kg/day, 5 days per week for 20 weeks where Ac.f was reported to increase 20-fold in tibiae 
(43.8) (71). The higher Ac.f for PTH was associated with increased sL.On/Ct.Ar, dL.On/Ct.Ar, 
and Rs.N/Ct.Ar – findings again consistent with this previous PTH trial (71). Activation 
frequency was also reported in rabbits receiving a lower dose of PTH, 10 µg/kg/5 days per week, 
for 35 days. Due to this lower dose, Mashiba and colleagues (83) reported only a 2-fold increase 
in Ac.f (29.3) in comparison to aged-matched controls. While it has become standard to include 
only labelled osteons in Ac.f, Frost’s early description indicated the numerator of Ac.f should be 
“the number of bone-forming or resorbing centers” (4). Thus, to overcome some of the 
limitations of Ac.f, and provide a measure of overall remodeling rate/activity that included the 
GC-dosed groups, we calculated a measure of active remodeling centers, a.Rm.Cr/Ct.Ar, which 
was not normalized to any assumption about osteon formation time and included both labelled 
osteons and resorption spaces. By this measure OVX and PTH were elevated related to SHAM 
7- and 13-fold, respectively, and the approximately 3-fold increases for GC and OVX+GC 
suggest a difference in those groups as well. This observation for the glucocorticoid groups was 
corroborated by the large fold-changes in Rs.N/Ct.Ar with p < α for OVX+GC. OVX and PTH 
also exhibited elevated radial mineral apposition rates (On.MAR) within forming osteons, 
providing corroborating evidence of an increase in the formative activity of BMUs. Conversely, 
the ratio of labelled osteons to resorption cavities ((sL.On + dL.On)/Rs.N) was reduced for 
OVX+GC (0.1 fold, p < α)  and GC (0.4 fold) indicating a lack of transition from bone 
resorption to formation (uncoupling (133-135)) in the glucocorticoid groups. Taken together, the 
histomorphometric data support the hypothesis that the rate of remodeling was elevated in all of 
these OP models, although the evidence for the GC was less robust than the other groups.  
Measures of cortical geometry and associated bone strength were largely unchanged 
across groups which was not unexpected given the skeletal maturity of the animals and the short 
duration of the experiments. The exceptions to this were changes in several parameters for GC 
associated with the distinct endosteal resorption observed in the glucocorticoid groups whereby 
large packets of bone were being resorbed with no evidence of formation within them. Whether 
these spaces reflect uncoupled BMUs (133-135) or a negative (resorptive) modeling drift (4) is 
perhaps a semantic point. It did not appear that these resorptions represented trabecularization of 
the cortex created by coalescence of numerous individual BMUs. Notably, this pattern of 
thinning cortices through increased endocortical bone resorption has been reported in GC treated 
rats (174). A previous report noted decreased cortical bone volume in GC treated rabbits (159). 
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For OVX+GC, Liu and colleagues (153) reported no significant changes in Ct.Th, whereas 
Chandler and colleagues (163) found significantly lower Ct.Ar and Ct.Th. For the current study, 
it was unclear if the decline in Imin we observed in GC was indicative of localized changes in 
porosity and/or cortical thickness related to mechanical axes. Given the non-random distribution 
of cortical pores visually apparent across all the groups, more detailed analysis of the interplay of 
mechanical axes and regional variation of bone microarchitecture across all envelopes 
(periosteal, intra-cortical, and endosteal) is certainly warranted.   
Endosteal bone apposition induced by PTH administration has been well documented in 
animal (71, 83, 91, 105, 150) and human studies (54, 55) and it has been suggested that this bone 
formation may be compensating for the increase in intracortical porosity to limit negative 
biomechanical effects (71, 87). We observed extensive endosteal bone formation for PTH, which 
uniquely had a trabecular-like appearance in 2D and 3D (Figure 3.4 E & F). It has been 
suggested that this may be poorly developed woven bone (150), a tissue type formed in states of 
high turnover/growth. Previous PTH rabbit studies have demonstrated small decreases in Ma.Ar 
(71) and increases in Ct.Ar (71, 83, 105). Hirano and colleagues (71) also found rabbits treated 
with PTH increased Tt.Ar, which was associated with periosteal bone formation, while several 
other large animal studies showed that the measure remained unchanged (83, 85, 87). We 
observed increased bone formation at both the endosteal and periosteal surfaces for PTH, 
although this did not translate into changes in overall geometry relative to SHAM, which may be 
due to our relatively short dosing period of 4-weeks. 
Our final objective was to contrast trabecular bone differences in the proximal tibia to 
facilitate contextual comparisons within the literature and compare effects across bone 
morphotypes. Previous reports are conflicted with respect to the effect of OVX on trabecular 
bone microarchitecture with one observing changes (175) and two others reporting no change 
relative to sham operated controls (153, 154). For the former, BV/TV and Tb.N were reduced 
and Tb.Sp increased in OVX rabbits compared to controls (175) at 27 weeks post OVX. For our 
study, Tb.N was reduced in OVX and the CI of BV/TV suggests a change in this parameter 
should not be ruled out. GC has been reported to reduce BV/TV (154) as well as reduce Tb.Th 
and Tb.N (159), while OVX+GC rabbits have also been reported to have reduced Tb.N, Tb.Th, 
Tb.Sp and BV/TV (153, 154, 162). Our findings of reduced BV/TV driven by a decline in Tb.N 
for both glucocorticoid groups are consistent with these previous reports.  
Trabecular bone formation induced by PTH administration has been extensively 
characterized in animal and human studies (61, 80, 176-179) although increases in rabbit 
trabecular bone have been less consistent. In the lumbar vertebrae of rabbits, PTH at a dose of 10 
µg/kg/day for 35 days increased BV/TV and Tb.Th; however, continuing PTH administration for 
an additional 35 days resulted in no differences in these parameters (83). Hirano and colleagues 
(71) also reported no difference in trabecular parameters when rabbits were treated with 40 
µg/kg/d for 20 weeks. We observed higher Tb.N in PTH and, similar to OVX, CI values suggest 
a change in BV/TV cannot be ruled out.  
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 This study has several limitations. First, while our group sizes (n=7) match the scale 
utilized in previous characterizations of the rabbit for trabecular bone and cortical 
geometry/density (152, 153, 161, 162), a great deal of variation was observed for many 
parameters, including outliers. Given there were no grounds to exclude them, all outliers were 
retained within our quantitative analyses. These factors ultimately limited our statistical power 
and certainly contributed to the uncertainty in a number of parameter changes despite 
considerable fold changes. Caution is thus warranted when determining significance of changes 
based upon p values alone, particularly where adjustments to α for multiple tests can make these 
comparisons occur on a very small scale. Consideration of CIs adds important contextual 
information but it must also be recognized that CIs are directly related to α. The necessity of 
additional tests to calculate adjusted CI and discrepancies detected with the primary statistical 
tests further highlight the perils of relying strictly on p value for analysis. As already noted, 
sample size limitations were further exacerbated by the lack of labelling in the GC-dosed groups 
and the low numbers of double labelled osteons in OVX and SHAM. Second, for our micro-CT 
analysis, we employed an imaging resolution (10 µm voxels) that was effective at detecting 
porosity on the scale of remodeling-related resorption spaces; however, it was insufficient to 
detect all vascular-level cortical porosity in rabbit bone (Supplemental Figure 3.81). Further, 
while this approach was effective at detecting resorption spaces, it is not exclusive to them and 
larger canals that were not actively remodeling as well as some of the porosity associated with 
endosteal bone formation (particularly evident in the PTH group) contributed to the overall Ct.Po 
measure. While the lack of bone formation observed within the GC-dosed groups is consistent 
with uncoupling within the BMU associated with GC treatment reported by Andreasen and 
colleagues (133), the shift towards larger sizes suggests a further disruption of BMU regulation 
through either a coalescence of resorption spaces (initiation and/or steering) or an increase in the 
size of individual spaces. Turning to our histological measures, a limitation of our measure of 
Rs.N/Ct.Ar and hence also a.Rm.Cr/Ct.Ar, was the fact that not all large spaces observed in the 
histological images could be confirmed as actively resorbing at the end of the experiment. This 
was particularly the case for the OVX groups (OVX and OVX+GC) which had a longer 
timeframe during which remodeling could be initiated and potentially halted/uncoupled. That 
said, due to our inclusion of only those spaces with roughly eroded surfaces, no lamellar bone 
formation, and no calcein labelling, it is a fair assumption that these spaces overwhelmingly 
represented recently active events induced by OVX and/or subsequent dosing. A more refined 
delineation of pores (i.e.., eroded, mixed eroded and formative, formative and quiescent pores) 
has recently been described (180) and presents a potential path forward for estimating the 
relative size/duration of the different phases of the BMU through their relative occurrences in 2D 
section. Such analysis paired with 3D morphological analysis of BMUs by micro-CT hold great 
potential for advancing our understanding of BMU spatio-temporal coordination. Expanding 
analysis beyond pores to the vasculature contained within them also holds great potential (181) 
as factors like age and corticosteroids reduce bone perfusion while PTH has been shown to 
increase it (182). Finally, a detailed analysis of the biomechanical impacts of increased porosity 
	 51 
was beyond the scale of this study. The non-uniform distribution of porosity indicates that 
careful consideration of sampling sites would be critical in examining the impact of these models 
on bone material properties.  
 
3.5. Conclusion 
 Our findings indicate that Ct.Po was elevated many fold for all treatments with the caveat 
that the data were the least robust for GC. Histomorphometric measures supported the hypothesis 
that remodeling rate was elevated in all groups with, again, GC exhibiting the least robust of the 
findings. For trabecular bone, a pattern of loss was observed for OVX, GC, and OVX+GC 
groups, while the opposite was observed for PTH. The viability of the OVX model, in particular, 
adds new evidence to the conflicted literature. Overall, our results are encouraging for the further 
exploration of the role of cortical bone loss in OP using rabbits and highlight the need to 
consider both cortical and trabecular changes when looking at systemic bone loss. These rabbit 
models also have great potential to serve as a platform for more detailed analyses of BMU 
spatio-temporal coordination and the balance between bone resorption and formation within 
individual remodeling events which cumulatively determine skeletal health. In this pursuit, in 



























Figure 3.81. Micro-CT Canal Diameter Resolution Dependency. A block of distal tibial cortical bone 
(1.5 mm x 3.0 mm) from a PTH animal was imaged at 2, 4, 6, 8, and 10 µm voxel using the instrument and 
protocols described in the materials and methods. 3D renders of a matching volume of interest from the 
highest (2 µm; A) and lowest resolutions (10 µm; B) are depicted. The size of the bounding boxes around 
the render is approximately 950 x 1300 x 2250 µm. Below, % volume distributions of canal diameter 
(Ca.Dm) (comparable to Figure 3D) are plotted for all resolutions (C) and for just the highest and lowest 
resolutions with the former histogram data rescaled to match the latter (D). At 2 µm, there is intermittent 
detection of osteocyte lacunae as well as detection of quiescent primary and secondary canals whereas at 
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10 µm only the largest of pores, corresponding to active or recently active remodeling centers, were 
resolved. The pore size distributions quantitatively reflect what was visible in the 3D renders.  As 
resolution was reduced, there was a loss of smaller pores and thus larger pores increasingly dominated the 
% volume distributions. Since the higher resolutions have smaller histogram bins (C) the contributions of 
each of these is relatively smaller, explaining the upward trend in percentages evident. When the histogram 
bin sizes were rescaled (C) it was clearly apparent that the higher resolution had a larger % contribution of 
smaller canals than the lower resolution scan. Notably, however, both distributions had a peak at the 
expected (~100 µm) size of normal rabbit secondary osteon diameter. Our analysis proceeded with the 10 
µm voxel size as it afforded good characterization of remodeling-related pores, maximized field of view, 
minimized data size and, ultimately, exceeded resolutions previously employed to characterize cortical 





Figure 3.82. Validation of Micro-CT Assessment of Canal Diameter. To validate 3D micro-
CT based measurements of Ca.Dm, the size (Feret’s diameter) of up to 20 resorption cavities 
from each animal was assessed manually in 2D from the confocal DIC images using ImageJ. 
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Matching the analysis presented in the manuscript, mean 2D Ca.Dm was assessed by ANOVA 
with pairwise post-hoc tests against SHAM. As depicted in A, 2D Ca.Dm was greater than 
SHAM for GC, OVX+GC, and PTH – an overall result very similar to that of 3D Ca.Dm with 
the exceptions that GC was significant in 2D and not 3D and PTH was significant in 3D but not 
2D. Bland-Altman plots revealed a significant but expected bias between the approaches with the 
3D micro-CT measure generating lower values (22.0, one sample t test vs. 0, p < 0.001) due to 
the inclusion of canals ranging from the maximum diameter of cutting-cones down to the limits 
of the 10 µm nominal resolution (see Supplemental Figure 1). While different, the two 
approaches produced significantly correlated results (r = 0.474, p < 0.005 overall; r = 0.668, p < 
0.001 with the exclusion of the outlier evident in B; Pearson’s, p < 0.01). Superimposed 
distributions of Ca.Dm from the experimental groups (C) were strikingly similar to the 3D 
equivalent shown in Figure 3 D. Superimposed distribution plots for the individual groups (D-H) 
clearly demonstrate the similarity of the two techniques with the 3D measure having a larger % 
volume contribution of smaller canal diameters. As noted for the 3D analysis in the manuscript, 
peaks at the expected size of 100 µm size of normal rabbit secondary osteons were observed in 
all groups except for those dosed with GC. These had distributions skewed towards larger canal 
diameters. Given the similarity between these approaches, despite fundamental differences in 

















Figure 3.83. Variation in Cortical Porosity Within the Tibial Diaphysis. We explored variation in 
cortical porosity along the tibial diaphysis in order to select the optimal site for analysis, balancing the 
goals of suitability for future in vivo imaging and maximizing the detection of porosity/remodeling. 
Left tibiae (contra-lateral to those analyzed in the manuscript) from two animals from each of our 
experimental groups were imaged along their entire diaphyseal lengths using the 10 µm resolution and 
protocol previously described in the materials and methods. The tibiae had to be bisected in order to fit 
into the scanner. The presented results recombine the data with the caveat that some minimal data were 
lost at the location of the cut, which was placed just distal to the tibio-fibular junction. Mean percent 
cortical porosity (Ct.Po, %) for the two animals from each group was plotted relative to the position 
along the diaphysis starting at 1 cm from distal tibial plafond. A 200-slice (2 mm) rolling average was 
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utilized to reduce noise and better facilitate comparisons across groups. Representative 2D cross-
sectional images along the diaphysis are presented for context (A-C; scale bar = 1 mm). The pattern 
was similar across groups despite variation in the overall level of Ct.Po. Porosity was lowest in the 
mid-diaphysis and increased proximally and distally. At the point of the tibio-fibular junction Ct.Po 
increased markedly and continued to do so proximally before eventually declining towards the 
proximal epiphysis. Considering suitability for in vivo imaging, overall porosity level, and anatomical 
complexity (e.g., one vs. two bones), the distal tibia ultimately presented the best overall target for our 
analysis. The variation along and within the diaphyses was intriguing and warrants further analysis 























CHAPTER 4. Conclusion  
4.1. Thesis Overview 
Despite the growing recognition of cortical bone remodeling and microarchitecture in 
osteoporosis, our knowledge of the spatio-temporal behaviour of BMUs is limited, and therefore 
fundamental aspects of bone remodeling remain poorly understood. The emergence of high 
resolution imaging tools like micro-CT have enabled us to assess cortical porosity and move 
away from predominantly trabecular focused studies given the growing recognition of the role 
cortical bone microarchitecture plays in bone loss and fragility. Combining synchrotron radiation 
micro-CT imaging with the appropriate animal model has the potential to directly track 
individual BMUs in vivo and permit us to gain novel insight into the coordination of remodeling 
events. Animal models are essential for the study of the factors that affect bone remodeling and 
contribute to the pathogenesis of OP. The rabbit in particular, is a suitable animal model for in 
vivo imaging because it is the smallest laboratory animals to exhibit bone remodeling. Because 
remodeling rates are naturally low in normal rabbits, experimental approaches that increase 
cortical bone turnover are necessary in order to establish a viable model system. Parathyroid 
hormone has well-documented effects on cortical bone in rabbits, stimulating bone turnover to 
increase cortical porosity. The aim of this thesis was to develop a rabbit model of cortical 
porosity using PTH, one of which would be capable of advancing the study of bone remodeling 
and have the potential for 4D tracking of cortical porosity using synchrotron-based imaging in 
vivo. 
Chapter 2 explored the effects of intermittent and continuous PTH administration on 
animal and human bone. The actions of PTH on bone seem to be dependent upon the mode of 
PTH administration (intermittent vs. continuous), duration of PTH administration, as well as the 
compartment (trabecular, cortical, endosteal, and periosteal) and site (vertebrae, tibia, etc.) of 
bone. It has been reported that intermittent PTH promotes bone formation on trabecular, 
endosteal, and periosteal bone surfaces, resulting in an increase in bone mass and an 
improvement in bone microarchitecture. This bone apposition has been associated with early 
modeling based bone formation, followed by remodeling and modeling based bone formation. 
Bone anabolism is mediated through actions on the osteoblastic cell lineage to increase 
osteoblast number and therefore bone formation. In addition to promoting bone apposition, 
intermittent PTH increases intracortical porosity by stimulating bone remodeling. In contrast to 
intermittent PTH administration, high circulating levels of PTH, as indicated in patients with 
PHPT, results in more deleterious changes in bone, mediated by pathways that prolong the action 
of osteoclasts. The cellular mechanisms that underlie the differential effects of PTH are currently 
not well understood, although it may be the case that different cellular mechanisms may be 
operating with each mode of administration, or at distinct bone sites. Studies evaluating the 
effects of intermittent PTH on rabbit bone have shown that their cortices respond to PTH with 
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increased turnover and intracortical porosity, which is ideal for establishing an animal model 
focused on cortical bone.  
Chapter 3 presented the main study whose aim was to develop several rabbit based 
models of elevated cortical porosity, one of which was the focus of this thesis, the PTH rabbit 
model. Cortical porosity changes were characterized in several models of OP (OVX, GC, and 
OVX+GC) relative to a SHAM control and compared against the cortical bone microarchitecture 
of the PTH model. Trabecular microarchitecture in the proximal tibial epiphyses was assessed 
secondarily. Morphometric analyses by ex vivo micro-CT imaging and histomorphometry 
revealed Ct.Po to be substantially elevated in the tibiae of PTH rabbits relative to SHAM. This 
was associated with increases in bone remodeling rate (Ac.f), the number of actively resorbing 
and forming osteons (a.Rm.Cr), and cortical pore size (Ca.Dm), although the distribution of pore 
sizes revealed a similar peak to SHAM at 100 µm. OVX, OVX+GC, and GC rabbits exhibited a 
similar but less pronounced pattern of elevated porosity and remodeling, with GC having the 
least robust effect, likely due to high levels of variation in the results and a small sample size.   
While losses were observed intracortically in the tibiae of PTH rabbits, the opposite 
effect appeared to occur within the trabecular compartment of the proximal epiphysis, as Tb.N 
and BV/TV were elevated and Tb.Sp was reduced, although these changes were more subtle than 
parameters of cortical bone remodeling. On the surfaces on cortical bone, histomorphometric 
analyses revealed extensive endosteal and periosteal bone formation, reflected qualitatively by 
prevalent calcein labelling and quantitatively by elevations in Es.MS/BS and Ps.MS/BS. A 
notable observation in these sections was the trabecularized appearance of some of the endosteal 
bone that had formed within a few of the PTH rabbits. This pattern is a typical feature of woven 
bone, however additional histological analyses (ie., collagen fiber orientation assessment with 
polarized light microscopy) would be needed to confirm its presence. Intracortically, PTH 
elevated the rate of new bone deposition within osteons, as indicated by an elevation in On.MAR 
relative to SHAM. Despite elevations in Ct.Po, the bending rigidity (Imax, Imin, Zpol) of the cortex 
did not differ from SHAM, which may be associated with the bone apposition on the endosteal 
and periosteal bone surfaces as well as the non-uniform distribution of intracortical pores, but 
further biomechanical analyses are required to fully understand these effects. 
In contrast to the PTH model, OVX, GC, and OVX+GC rabbits tended to lose bone in the 
trabecular compartment and on cortical bone surfaces. A pattern of bone loss was observed in 
OVX, GC, and OVX+GC groups evidenced by reductions in BV/TV for GC and OVX+GC 
groups and Tb.N for GC, OVX+GC, and OVX groups. A more subtle change in Tb.Sp in these 
groups also supported this pattern of loss. Pronounced scalloping of the endosteal surface of 
rabbit tibial cortices in GC dosed rabbits (GC, OVX+GC) was observed and image-based 
estimates of bone strength (Imax, Imin, Zpol) in GC rabbit cortices were reduced. The latter result 
could be related to the smaller cortices (Ct.Ar) of the GC rabbits or the presence of intracortical 
pores. While all model systems exhibited evidence of intracortical bone loss to varying degrees, 
the 2D and 3D results indicate PTH induces bone remodeling that is quite distinct to that of OVX 
and GC models in terms of the porosity observed and the unique structural changes it produced 
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within various bone compartments. This is likely the result of variation in the mechanisms by 
which cortical porosity develops. For instance, PTH increases the rate of remodeling as well as 
the initiation of new BMUs to elevate porosity whereas BMU uncoupling (133) appears to be the 
predominant mechanism mediating GC-related bone loss as evidenced by a lack of calcein 
labelling and large intracortical pores within histological sections of GC dosed rabbits. Further 
exploration into these differences is required to better understand how BMU behaviour varies 
and how this variation impacts BMU morphology, which contributes to the resulting cortical 
bone structure. These results also highlight the importance of considering the bone as a whole 
when evaluating overall OP related bone loss. 
Within this study, all rabbit based-models exhibited elevations in Ct.Po and cortical bone 
remodeling, with GC having the most varying effects in cortical bone, and PTH exhibiting the 
most dramatic effect in cortical bone. Parathyroid hormone was an ideal agent for developing a 
cortical bone model for this study because it was well tolerated by the rabbits and it induced the 
greatest level of porosity amongst the models within a relatively short time frame. Overall, the 
models described in this study are all good candidates for future longitudinal in vivo imaging to 
dynamically study their complex cortical networks. These models can serve as a platforms for 
further investigations into the intriguing effects that PTH, OVX, and GC impart on cortical and 
trabecular bone compartments and opens up new opportunities for mechanistic studies that test a 
number of hypotheses related to BMU regulation so we can better understand remodeling and its 
role in adaptation, aging, and disease.  
 
4.2. Future Directions  
The PTH rabbit model can be utilized to explore many avenues of research related to the 
bone remodeling process and other PTH effects in bone. One of the primary reasons for 
developing this model system was to establish a platform for which cortical bone remodeling 
events could be tracked by means of longitudinal synchrotron based micro-CT imaging. The 
rabbit model described in this thesis has now been implemented at the Canadian Light Source 
(CLS) on the BioMedical Imaging and Therapy Insertion Device beamline to achieve this goal 
and directly measure LER for the first time (manuscript in preparation). This was a project I had 
the opportunity to be involved in during my MSc program. In brief, distal rabbit tibiae were 
imaged in vivo at the CLS after 2 weeks of PTH dosing, dosed with PTH for an additional 2 
weeks, and then imaged at the same region ex vivo using high-resolution conventional micro-CT. 
The two micro-CT scans were then co-registered using 3D data analysis software, so that LER 
could be directly measured from individual BMU related resorption spaces. LER was measured 
as the distance between the cutting cones at Time 1 and Time 2 (Figure 1.5). This study not only 
contributes to our basic understanding of bone remodeling by directly measuring cutting cone 
advance for the first time, but this platform allows us to better understand how PTH affects the 
coordination of bone remodeling events, since it is being utilized to induce bone turnover. This is 
clinically significant since PTH is both an anabolic treatment for OP when administered 
intermittently and a cause for secondary OP with high circulating levels. Results from this study 
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can be applied to designing future longitudinal experiments aimed at investigating specific 
aspects of the bone remodeling process as well as the physiological mechanisms underlying 
PTH’s intriguing effects on bone. Some of these potential experiments utilizing this platform 
could involve: 
• Studying the impacts of mechanical loading on BMU behaviour. It has been 
speculated that BMU activity is influenced by mechanical stimuli as the 
orientation of secondary osteons have been shown to align with the principal 
stresses of long bones (183). Furthermore, it has been proposed that cortical bone 
remodeling may be initiated by micro-damage induced by repetitive mechanical 
loads and that BMUs actively “steer” towards these areas to remove damage 
(184, 185). To test this hypothesis and evaluate the impact of mechanical loading 
and overloading on BMU coordination, PTH could be employed to induce a 
wave of remodeling in rabbits before altering the mechanical load. Rabbits dosed 
with PTH could be imaged in vivo immediately before manipulation of the 
mechanical load and ex vivo after a period of adaptation. This methodology 
would facilitate the direct tracking of existing BMUs present at the time of 
intervention so that any changes in their behaviour or orientation that occurred in 
response to various mechanical stimuli, could be quantified. Intrinsic mechanical 
loading could be applied by exercising previously sedentary PTH rabbits. 
Mechanical overloading could be achieved by axial loading of the tibia to 
produce micro-damage. To date, axial loading in rabbits has only been achieved 
in the forelimb (186), so this model would need to be adapted to the tibia. In the 
case of the axial loaded model, longitudinal imaging would indicate if existing 
BMUs alter their trajectories to target micro-damage induced by overloading.  
• Studying the impact of mechanical unloading on BMU behaviour. On the other 
end of the loading spectrum, a lack of loading, or unloading, has been shown to 
increase cortical remodeling resulting in bone loss, as seen in individuals who 
experience prolonged therapeutic bed rest or are in weightless environments (ie., 
spaceflight) (187). To assess BMU activity in response to reduced mechanical 
loads, PTH rabbits would be imaged in vivo before undergoing single limb 
immobilization, which can be achieved through casting or neurogenic paralysis 
of the hindlimb (188). Similar to the loading experiments, tibiae would be then 
be imaged ex vivo after a period of adaption. The results from such a study would 
shed light on the mechanisms that underpin unloading associated bone loss.  
• Assessing BMU behaviour in response to injury. Related to the mechanical 
loading and unloading experiments above, one could test the hypothesis that 
BMUs alter their course through bone tissue to target localized injury induced in 
PTH rabbits. A cortical bone defect could be produced in the tibia of a PTH 
rabbit by osteotomy using a surgical drill (189). Alternatively, injury in the form 
of a surgical implant or by selective irradiation could be utilized. Longitudinal 
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imaging during the healing period would determine if BMUs are directed 
towards regions of localized injury and provide more insight into the mechanisms 
that are involved in bone repair. 
• Investigating PTH’s distinct effects on bone compartments by manipulating the 
duration and frequency of PTH administration and imaging rabbits in vivo. One 
example could include assessing effects of once daily PTH, once weekly PTH, 
and continuous PTH on bone in 3D and 4D. The latter would involve developing 
a model of hyperparathyroidism in the rabbit. Currently, PHPT has only been 
induced in rabbits by a high phosphate diet (121, 122) although, cortical bone 
microarchitecture in these models have not yet been extensively characterized. 
Hyperparathyroidism has been induced in mice and rats by continuous PTH 
administration using subcutaneous infusion pumps (109, 111) or through the 
generation of transgenic models (190), so there is a potential of utilizing these 
interventions to induce the disease in rabbits in future studies. 
• Imaging PTH dosed rabbits in vivo at multiple time points to detect changes in 
porosity and cortical geometry over time in order to evaluate the temporal nature 
of PTH bone effects. One could test the hypothesis that bone formation induced 
by PTH would be maximal at early time points during the experiment, which 
would provide compelling evidence for the concept of the  “anabolic window” 
that is said to occur early in treatment (92, 93).  
• Studying the effect of PTH withdrawal on BMU progression and cortical bone 
microarchitecture. This project has recently been undertaken in our lab utilizing 
the PTH dosed rabbit model and longitudinal synchrotron radiation based 
imaging platform. Using the dosing protocol described in this thesis, rabbit tibiae 
were imaged at the CLS in vivo after being dosed with PTH for two weeks. Half 
of the rabbit cohort then ceased PTH administration while the other half 
continued with the same dosing regimen for an additional two weeks. After this 
time, rabbit tibiae were imaged at the same region ex vivo, with desktop micro-
CT. From this study, one can determine if PTH withdrawal alters the rate of 
BMU progression, which not only provides more insight into the bone 
remodeling process but also holds great clinical significance, as treatment 
discontinuation and long-term effects are important factors to take into 
consideration with OP treatments. OP patients who take teriparatide as an 
anabolic treatment are only permitted to take it for up to 2 years (11). There is a 
lack of consensus in the literature regarding the effects of PTH withdrawal on 
bone such that one clinical study has reported a decline in BMD in post-
menopausal women after teriparatide discontinuation (191), while another found 
a sustained reduction in vertebral fracture risk in post-menopausal women 18 
months after ceasing teriparatide treatment (192). Although limited in duration, 
this study would yield novel 3D and 4D information on how PTH withdrawal 
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impacts cortical bone remodeling, which could be applied to developing efficient 
OP therapies that improve long term therapeutic outcomes and limit adverse 
effects related to treatment discontinuation. 
• Producing a more clinically relevant model system by dosing OVX rabbits with 
PTH at a dose similar to what is given in the anabolic treatment of OP 
(teriparatide, 20 ug/ day (11)) and then imaging rabbits at different time points to 
assess PTH effects in a model of primary cortical bone loss (postmenopausal 
OP). This would help us understand the mechanisms by which PTH acts so that 
we can optimize current treatments or design novel therapeutic interventions to 
more precisely control bone remodeling and to maximize anabolic effects.  
• Imaging rabbits dosed with PTH in combination or in sequence with an anti-
resorptive agent like bisphosphonate, to permit a greater understanding of the 
action of current OP therapeutic interventions on bone. Combined therapy (193) 
and sequential therapy (194) with PTH are more recent therapeutic approaches to 
combat bone loss in OP patients and results from such studies could be compared 
and contrasted against monotherapy. 
In addition to longitudinal imaging studies, the PTH dosed rabbit model could also be 
utilized to quantify 2D parameters of bone remodeling by means of histology, such as measuring 
closing cone advance and reproducing the histological measure of LER from the classic studies 
from the 1970s (28, 29). Histological LER could be quantified in both the PTH dosed rabbit 
model and in the SHAM control to compare against previously established measures. 
Additionally, these values could also be compared against direct measures of LER from the same 
animal to assess the validity of the measure. In order to measure LER in 2D, serial longitudinal 
sectioning of undecalcified bone is required for morphometric evaluation. I have worked on 
optimizing the methodology for this protocol during my Master’s program for the quantification 
of histological LER (Appendix A), but this technique can also be applied to any future cellular 
analyses requiring thin sections. The two techniques I have focused on optimizing is physical 
sectioning, where an entire section of bone is cut into very thin sections of 5-10 µm thickness, 
and optical sectioning, where sequential images are taken throughout the region of interest to 
produce an image stack. Physical sectioning can be achieved through plastic or frozen bone 
sectioning. Plastic sectioning requires undecalcified bones to be embedded in a medium that is 
similar to the hardness of bone, like methylmethacrylate (MMA) before being thinly sectioned 
using an automated heavy-duty rotary microtome. Sections are then mounted on glass slides for 
analysis. Methylmethacrylate is optimal for LER analysis because it preserves and supports the 
2D and 3D structure of bone tissue, permits the visualization of fluorescent labels, and exhibits 
minimal auto-fluorescence during imaging (195). Frozen sectioning, also known as 
cryosectioning, requires bone to be embedded into a frozen block before being thinly sectioned 
with a cryostat and transferred onto glass slides. The sections produced with either technique are 
then imaged with a microscope possessing fluorescent capabilities and visualized in 3D by 
rendering the image stack. Alternatively, optical sectioning can achieve similar results, having 
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the advantage of being minimally destructive in comparison to physical sectioning. By utilizing 
the z-stack imaging tool on the confocal microscope (taking images along the z dimension of a 
bone), one can create a 3D render from the stack of images taken from a thick section of bone. 
With this technique, the bone is best preserved by first being embedded in MMA before being 
cut into a thick section and then mounted on a glass slide. These protocols are described in more 
detail in Appendix A. Reproducing the measure of histological LER using the sectioning 
techniques described above would provide a means for analyzing osteoblastic and osteoclastic 
activity at the tissue level, which is informative for our understanding of bone remodeling 
dynamics, especially if histological sections can be matched to a 3D micro-CT scan of the same 
BMU related resorption space. 
Aside from being employed in studies characterizing dynamic properties of BMU 
activity, the PTH dosed rabbit could be used to further characterize some of the interesting bone 
structural outcomes observed within these rabbits. Future studies investigating the role the 
unique endosteal bone formation and the non-uniform distribution of cortical porosity plays in 
determining the overall strength of bone would be useful, considering the level of porosity 
induced by PTH. Currently, our lab is investigating this by performing image based 
biomechanical analyses on sections of the tibiae from this rabbit model. Future studies could also 
focus on characterizing the morphology of BMU related resorption spaces created by PTH and 
associated vasculature, since PTH induced remodeling that was quite distinct from the other 
rabbit OP models, and these morphologies could be compared to those of GC and OVX rabbits. 
Within the tibiae of PTH dosed rabbits, we observed BMUs of various morphologies including 
classic cutting cones as well as highly branched clusters. Since morphology is a direct outcome 
of osteoclastic and osteoblastic activity, morphological analyses of BMUs in this model may 
provide additional lines of evidence for some of the PTH driven alterations in bone remodeling 
that are thought to occur, for instance, the shape of a BMU related resorption space in this model 
may indicate an increased rate of closing cone advance. Finally, it would be interesting to assess 
the same bone microarchitectural parameters analyzed in the main study in different bones 
within the rabbit, like the femur and humerus, to determine if there are any site specific effects or 
variation in porosity within this rabbit model. 
Overall, this thesis introduced a highly reproducible and efficient experimental cortical 
bone model in the rabbit using PTH, as apart of a larger study surveying rabbit-based models of 
elevated cortical bone remodeling, thereby establishing a platform for studying how cortical 
porosity develops and how it may contribute to the pathogenesis of OP. The information gained 
from this thesis will inform future studies investigating BMU regulation and variation as well as 
the mechanisms underlying the complex and multifaceted effects of PTH on bone 
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My master’s thesis project initially aimed to measure LER histologically in the PTH rabbit 
model to compare against previous characterizations of LER as well as to direct measures 
derived from longitudinal in vivo imaging studies. This appendix outlines several of the 
histological protocols I explored to produce longitudinal sections of undecalcified bone for 
measuring LER based on the bone microarchitecture and in vivo fluorochrome labels that a 
future graduate student can build upon.  
A.1. Methylmethacrylate Embedding for Undecalcified Bone 
The following protocol will produce sections of bone embedded in methylmethacrylate (MMA) 
that can be utilized for thin serial sectioning or for optical sectioning with confocal microscope. 
The Osteobed Bone Embedded Kit is recommended for this protocol.  
 
Bone Processing 
1. Clean bones of soft tissue.  
2. Cut bones to desired length using a Beuhler Slow Speed Isomet saw. For rabbit tibiae, cut 
the diaphysis into 0.5-1 cm long sections.  
3. Fix specimens in 10% neutral buffered formalin in a tightly closed container. Fixation 
time will vary depending on sample size. For the rabbit sections above, fix for at least 1 
week. Fixation rate can be accelerated by agitating or vacuuming.  
4. After fixation is complete, store bones in 70% ethanol until processing commences. This 
is ideal for long-term storage to prevent the loss of fluorochrome labels in bone caused by 
partial decalcification with prolonged fixation in formalin.  
5. Dehydrate bones in graded ethanol (EtOH) solutions as follows: 70% EtOH, 80% EtOH, 
95% EtOH, 95% EtOH, 100% EtOH, 100% EtOH, 100%, EtOH, xylene, and 100% 
EtOH. Processing time will vary depending on sample size. Specimens should be 
dehydrated in 10 times the volume of the sample. Vacuum specimens for 3-4 hours for 
each step and agitate samples. If a automated tissue processor is available, set it to run the 
following processing schedule:  
o EtOH 70% 6 hours, 80% EtOH 6 hours, 95% EtOH 3 hours, 95% EtOH 3 hours, 
100% EtOH 4 hours, 100% EtOH 4 hours, 100% EtOH 4hours, 50% EtOH/50% 
xylene 2 hours, xylene 6 hours, xylene 30 hours, 100% EtOH 6 hours.  




1. As per the instructions of the Osteobed Bone Embedding Kit, calculate the amount of 
pre-infiltration solution needed; all infiltration liquids should be 10 equivalent volumes of 
the specimen and be placed in 2 changes of pre-infiltration solution to allow removal of 
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alcohol and tissue fluids. Pre-infiltration should be completed under a fume hood and 
with limited exposure to direct light.  
2. Measure out Resin Solution in graduated cylinder and infiltrate specimens with Resin 
Solution in opaque plastic container with tight fitting lid.  
3. In fume hood, vacuum specimens at 15-20 in.Hg for 6-8 hours, releasing vacuum every 
30 minutes. Infiltrate in fume hood or in refrigerator for the remaining time until next 
change (~3 days). Pre-infiltration time may need to be modified depending on size of 
specimens. The recommendation in this protocol is for rabbit tibial samples 
approximately 0.5cm x 0.5 cm in size. 
4. Change pre-infiltration solution and repeat steps for an additional day.  
 
Infiltration 
5. Prepare infiltration solution one day prior to infiltration. Calculate the amount of 
infiltration solution needed; all infiltration liquids should be 10 equivalent volumes of the 
specimen to allow removal of alcohol and tissue fluids. The ratio is 1.4g Catalyst per 
100mL of Resin Solution. This should be completed under a fume hood and with limited 
exposure to direct light. 
6. Weigh Catalyst in weight boat and place into plastic container with tight fitting lid and 
magnetic stir bar.  
7. Measure Resin Solution using graduated cylinder. In fume hood, add Resin solution to 
opaque plastic container with tight fitting lid and stir for 4 hours with magnetic stir bar.  
Solution will become cloudy.  
a. Promptly store solution at 2-8°C. Solution can be stored up to 4 weeks.  
8. In fume hood, add infiltration solution into opaque plastic containers with tight fitting lid.  
9. In fume hood, vacuum specimens at 15-20 in.Hg for 6-8 hours, releasing vacuum every 
30 minutes. Repeat for ~3 days and refrigerator samples in between. 
 
Bone Embedding 
1. Prepare embedding medium one day prior to embedding. Calculate the amount of 
embedding medium needed according to volume of molds (19/65 mm 3 Dram (~10 ml) 
glass vials are recommended). The ratio is 3.5g of Catalyst per 100ml Resin Solution.  
2. Weigh Catalyst and measure out Resin Solution and place in opaque plastic container 
with tight fitting lid. Dissolve and mix for 4 hours with magnetic stir bar. This should be 
completed under a fume hood. 
a. Solution will become cloudy. Promptly store solution at 2-8°C. Store up to 4 
weeks.  
3. Place samples into opaque plastic container with embedding medium. Place into vacuum 
for 4 hours at 15-20 in.Hg. Tightly cap and leave in refrigerator to further infiltrate 
specimen and vacuum the next day for 4-6 hours (total infiltration ~48 hours).  
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4. Before polymerization step, prepare water bath setup at least 12 hours in advance. Pre-
heat oven with water bath (37°C). Check temperature with thermometer. 
5. Under a fume hood, place specimen into glass vial with forceps. For longitudinal 
sections, position the bone so that the longitudinal axis of the diaphysis is parallel with 
the base of the glass vial. Pipette embedding solution into glass vial with plastic pipette. 
Do not completely fill glass vials with resin as it may increase polymerization 
temperature.  
a. Optional: For a pre-polymerized base, pipette 3-5 mm of embedding solution into 
vial. Cap the vial and place into water bath for 2 hours to make viscous base 
before adding specimen and filling the rest of the vial with embedding solution. 
6. In fume hood, vacuum specimen for 1 hour in vials at 15-20 in.Hg to remove any trapped 
air in the specimen. 
7. After vacuuming, adjust final position of specimen to ensure it is centered within the vial 
and cap vial tightly. The presence of oxygen inhibits polymerization at the surface. Place 
vials into water bath at 37.0°C for at least 24-48 hours. Larger volumes may require 
longer polymerization times. Do not disturb container. Do not overcrowd water bath as 
this can increase polymerization temperature and cause bubbling.  
8. Remove blocks from molds when resin has fully cured. 
a. Place glass vial with sample block into bag with towels. Carefully smash vial to 
free sample block with cut resistant gloves. Carefully dispose of broken glass in 
the appropriate container.  
9. Remove any unpolymerized resin on top of block by scraping it off. Sample blocks can 
now be sectioned with a microtome to produce thin, serial sections or cut with a slow-


















A.2. Serial Sectioning of Undecalcified Bone with Automated Microtome 
The following protocol is for sectioning undecalcified bone in MMA using an automated 
microtome. This protocol uses the Microm 350S automated microtome. A sledge or sliding 
microtome would be ideal for this technique. Tungsten carbide blades are recommended for 
sectioning hard tissues like undecalcified bone.   
 
1. Retract sample holder of automated microtome in preparation for sectioning. 
2. Secure bone sample into holder and tighten the clamp using associated knobs. Align the 
sample to produce sections within the desired place.  
a. Ensure the block face of the sample is directly parallel to the holder.  
b. If needed, adjust the position of sample, by first releasing the sample holder 
clamp and then using the various adjusting knobs to modify the position of the 
clamp and sample. Re-tighten the holder when finished. 
3. Carefully place tungsten carbide blade into knife holder. First release the right block 
handle of the knife holder, insert the blade using forceps, and re-fasten. 
a. Ensure blade is level. 
b. Label the blades for future reference. Designate one blade for trimming and make 
note of which blades are used for sectioning.  
c. Before sectioning with a previously used blade, clean it in fume hood by wiping 
away any remaining residue from the blade with a Kimwipe dipped in xylene. 
Allow fumes to evaporate in fume hood for 2-3 minutes before sectioning.  
4. Adjust clearance angle and section thickness.  
a. Adjust clearance angle with right knob of holder (~4°). 
b. Set cutting speed at 4. 
c. Adjust the section thickness dial; 20 µm for trimming, 5-10 µm for sectioning.  
5. Bring the sample close to the blade by moving the knife holder backwards (release the 
left handle and slide backwards) with approximately 1 mm of space between. Use the 
automated extender button on the control pad to advance the sample closer to the blade.  
6. Ensure everything is secured tightly in place. This is very important for producing 
consistent, even sections as instability can induce chatter (vibration of blade edge). 
7. Start trimming the block. Use 30% EtOH to lubricate the block face before sectioning the 
block by rubbing an ethanol soaked Kimwipe over the blockface every few sections. 
Begin by trimming the block manually by turning the right wheel to produce a section. 
Make sure to remove any MMA or bone residue every few sections from the block face 
and the blade with a paintbrush for smooth and consistent sectioning and to prevent 
imperfections in section.  
8. Once you have reached the desired region of interest (ROI) of the sample, switch the 
blade to a new, sharp blade and start automatically sectioning the block by pressing start 
on the control pad. It is very important the blade is sharp for successful and consistent 
sectioning. Blades that contain nicks can introduce tearing of the section. The microtome 
will automatically advance the sample block to produce consistent sections of a desired 
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thickness. Thin sections of MMA with the sample will be produced that can be set aside 
with forceps.  
a. Press the red or yellow stop button to stop at any time or when finished.  
9. Place sections on glass microscope slides and flatten. This can be achieved by carefully 
stretching sections over slides with forceps and then covering with plastic wrap with 
weight to prevent the section from rolling up. Mount section onto slide with 
fluorochrome protective mounting medium and coverslip. Sections should be stored to 
avoid exposure to light (opaque slide box) in order to protect the bone fluorochrome 
labels. 
10. Once finished, carefully remove blade by releasing right handle of knife block, and using 
forceps to remove blade.  
11. Clean microtome and dispose of large MMA and bone residue into waste bag and 
remaining residue with 70% EtOH with Kimwipes.  
12. For analysis, image sections with a microscope with fluorescent capabilities to capture 



























A.3. Optical Sectioning of Bone with Confocal Microscope 
The following protocol uses the Leica DMi8 confocal microscope for analysis of thick ground 
sections of undecalcified bone embedded in MMA by z-stack imaging.  
 
1. Prepare Leica DMi8 microscope and associated software for imaging. 
a. Remove Microscope Cover.  
b. Ensure microscope stage is in its lowest position, on the lowest objective. 
c. Turn on laser (green switch on the large black system). 
d. Turn on microscope (switch on white electronic box). 
e. Allow microscope to calibrate. 
f. Turn on computer and open up LasX program (Machine, DMIS, ok). 
2. Ensure microscope slide is clean by carefully wiping it with a KimWipe and cleaning 
spray. 
3. Carefully tilt the transmitted light arm on the microscope backwards to place slide onto 
stage upside down. The sample should be facing down.  
a. The slide should fit into the indentations on the stage and held into place with 
metal clips. 
4. To turn on the light source, click the buttons on the motorized objective nosepiece and 
motorized fluo turret panel located below the eyepiece to open the shutter.  
5. Bring the section into focus and adjust its x-y position. Use course and fine adjusting 
knobs on side of microscope to focus on section and adjust x-y position using SmartMove 
controls to move the stage (white knobs).  
6. Once the ROI within the section is in focus, change objectives if desired. Rotate through 
the objective nosepiece (dial located under the stage- 10X, 20X, 40X, 60X) and adjust 
fine focus with each magnification.  
7. Before turning on laser system, turn off lights. 
8. In LasX program, make a new project. All subsequent images will be saved here. 
9. Use the combination of fluorescence and transmitted light differential interference 
contrast (DIC) for imaging. A previous scan with the desired image settings can be 
opened by locating the file, right clicking on it and selecting “Apply Image Settings”. 
This will prompt a window with a reminder to turn on the laser. Turn the key of the laser 
system to turn it on (big black box), and then press ok on the program to confirm. Oil 
immersion or dry immersion may be used. Depending on sample, image settings will 
need to be modified. For dry immersion, settings are set to: 
a. Objective: HXC PL FLUOTAR 5x/0.15 numerical aperture 
b. Wavelength excitation: 488 nm using TD 405/488/635 beamsplitter 
c. Laser intensity: 30% 
 
Adjust Imaging Parameters 
1. While modifying imaging settings, use the image format 512 x 512. 
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2. Adjust the settings for transmission and fluorescence axes separately by toggling between 
them using the sequential tab (bottom left hand corner). Start with fluorescence view.  
3. Click Live to project live view of section on computer so that you can simultaneously 
adjust settings.  
4. Use the z position knob on the control panel in front of the computer to move through the 
section and locate the region that emits the brightest fluorescence. Then use the fine 
focusing knob to adjust.  
5. Click on the icon on the top left corner (Quick Lookup Table button) to toggle to the 
detector signals to adjust the gain and the offset. This will allow the signal intensity and 
noise level of the image to be adjusted.  
d. To adjust Smart Gain (signal amplification), turn the 1st knob on control panel 
(left) to approximately ~700 V. 
i. In fluorescent image, ensure the pixels of detected signals of the 
fluorescent labels are mainly red and white, limiting the amount of blue 
pixels, which indicates an over-saturated signal. Lower the gain if there is 
too many blue pixels and increase gain to maximize brightness. The 
sample position may also need to be adjusted to find the optimal plane of 
section.  
e. To adjust Smart Offset (the minimum signal intensity detected by the sensor), turn 
the 2nd knob on black panel to approximately ~0.6%. 
i. In fluorescent image, background should be is mostly green with a little 
black (this indicates there is no signal/ noise). Adjust offset until black 
pixels just mostly disappear.  
ii. Click the icon in the top left corner to return to normal view.   
6. Click Stop, switch microscope settings to transmission and then adjust DIC image.  
7. Click Stop once adjustments are completed.  
8. Once the image has been adjusted to produce the desired image, snapshots of images can 
be taken by clicking on Capture. If both fluorescence and DIC are to be taken, select both 
views in the sequential tab. Rename the file under the project tree. 
 
Tiled Scan 
1. If specimen is large, utilize a tile scan. Click on the tiled image tab and use the imaging 
format 512 x 512 while adjusting image settings. Set image speed to 600. 
2. Click Live, find region of interest (ROI) on the section and adjust the image as above if 
needed.  
3. Click Stop and change image format to 2048 x 2048. 
4. Select field size as 5 x 5 or 10 x 10 (this depends on the size of the ROI to be imaged). 
5. In the stage window, zoom out to find the middle of the slide. 
6. Select Merge On.  
7. Select Start to begin tile scan.  
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8. Once tile scan if finished, you can repeat for all other ROIs. Once all tile scans are 
complete, delete the tiled scan tab or it will be applied to other scans (ie., standard images 
or z-series scans). The output will contain all of the individual tiled fluorescence and DIC 
images, as well as a complete, stitched together final image. 
9. Rename the tile scan under the project tree.  
 
Z-Series 
1. To create a 2D image stack, begin with the image format of 512 x 512. 
2. Click on Z series.  
3. Click Live, and adjust image of desired ROI.  
4. Use the fluorescence mode to set up z-stack.  
5. Define the volume of bone to be imaged: 
a. Using Z series knob (last knob on the right of the control panel), turn the knob 
counterclockwise until the top or “beginning” of the sample is reached. The image 
will appear blurry and the fluorescence will be faint. 
b. Once this limit is reached, click Begin under the z-series tab and turn the same 
knob clockwise until the bottom or “end” of the sample is reached Click on End.  
6. If needed, select move to center and adjust focus to find optimal image.  
7. Click Stop and select the 2048 x 2048 image format. 
8. Define the resolution of the z-stack by entering in desired z step size (~0.5-5 µm). Based 
on the image step, image and pixel size, the number of steps will be calculated and the 
optical section thickness will be produced. 
9. Select the z-series to run between frames (alternating between fluorescence & DIC 
images) or between stacks (will run stack through all fluorescence, then DIC).  
10. Press Start to begin Z series.  
11. Once finished, a 3D reconstruction of the z-stack can be visualized by clicking on the 3D 
icon in the top, right window. Additional modifications to the z-stack can be made in this 
program.  
12. When finished, rename the z-series under the project tree.  
 
Confocal Microscope Shutdown 
1. Save project by clicking on the Save icon to the right of the project tree. 
2. Begin shut down process of microscope. 
a. Switch off laser with Laser Key.  
b. Exit LasX software. 
c. Switch to 5x objective and lower stage to its lowest position.  
d. Shut down computer.  
e. Switch off supply unit at power switch.  
f. Switch off microscope (white box).  
g. Put microscope cover on microscope.  
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Z-Stack Assessment 
1. Open Leica file (lif) that contains the z-stack in Fiji or in Image J (with Bio-Formats 
plugin).  
2. A window will appear that contains a list of all the images collected within the project. 
Select the images or image series to be analyzed. Click OK.  
3. The selected project will open as separate z-stacks, for fluorescent and transmission 
(DIC) channels. The appropriate colour may need to be applied: Image > Lookup Tables 
> Grays for DIC images & Green for fluorescent calcein images. To assess fluorescent 
and DIC images together, merge the two image stacks by selecting Image > Color > 
Merge Channels and select the DIC image under the G4 Gray category and the 
fluorescent image under the C2 Green category. Keep source images. Click ok. To 
convert the 2 slice stack into an image, select Image > Color > Stack to RGB. Save the 
images in tiff format. 
4. A raw 3D render can be generated in by selecting Image > Stack > 3D Project.  
5. Further image processing in other 3D data visualizing software is required to produce the 





Figure A.1. (A-B) Fluorescent confocal and differential interference microscopy 2D 
image (z) stacks of a longitudinal section (~400 µm) of undecalcified PTH rabbit 
bone (from Chapter 3) depicting an example of a BMU from which LER can be 
measured from. In B, the white arrow indicates the tip of the cutting cone of the 
BMU and the red bar indicates the region where LER would be measured (between 





A.4. Cryosectioning of Undecalcified Bone 
The following protocol produces thin frozen sections of undecalcified bone. The Kawamoto Tape 
Transferring Method is recommended for this protocol. Materials for this method can be found 
at http://www.section-lab.jp/. This protocol utilizes the TBS cryostat.  
 
Cryo-Embedded Specimen Preparation  
1. Cryosections can be prepared from fresh or fixed bones. For fixation, place bone 
specimens in 10% formalin solution for at least 48 hours. Fixation time will vary 
depending on size of specimens. For 0.5 cm x 0.5 cm sections of rabbit tibiae, fix for 5-7 
days.  
2. Incubate bones in 30% sucrose in 0.1M phosphate buffered saline (PBS) for 1 week at 
4°C. 
a. 30% Sucrose: Dissolve 30 g sucrose in 70 ml 0.1M PBS. Once dissolved, make 
up volume to 100ml with 0.1M PBS. 
3. Prepare a large beaker (2000 ml) or Styrofoam container with dry ice and ethanol (2:1) 
under fume hood. Place small beaker (150-250 ml volume) with hexane (30-50 ml) inside 
container. Allow hexane to cool, approximately 10 minutes until frost appears outside of 
the small beaker.  
4. Fill ¾ of labelled square or rectangular mold (Polysciences Peel-A-Way molds are 
recommended) with Cryo-embedding medium. Supercryoembedding Medium (SCEM) is 
recommended but Optimal Cutting Temperature medium (OCT) can also be used. 
Carefully place specimens into molds until fully immersed taking care not to touch the 
edge of the mold. For rabbit tibiae, position longitudinal axis of diaphysis so that it is 
parallel with base of mold. Make sure bubbles are removed. With forceps, hold the 
cryomold with the specimen into the beaker so that the bottom of mold just touches the 
surface of the cooled hexane.  
5. Allow the outer edges of the embedding medium to freeze (indicated by opacity, 
approximately 15 seconds). Fully drop the mold into the hexane and allow freezing for 1-
2 minutes. Once frozen, remove sample from hexane and immediately wrap it in 
cellophane and aluminum foil to prevent it from drying out or being exposed to light.  
6. Repeat for other samples, adding additional dry ice to ethanol to ensure quick freezing of 
specimens. Store samples at -80°C until sectioning commences.  
 
Cryo-Sectioning 
1. Set the cryochamber temperature to -24°C /-25°C. 
2. Place frozen sample block in cryochamber to acclimatize for at least 1 hour. 
3. Prepare cryofilm (Cryofilm Type 3C- 16UF, 2.5mm) by cutting sheets into sections large 
enough to just cover the ROI of the specimen in the frozen block. Place into cryostat to 
chill. Pre-chill roller, small paintbrush, slides, and forceps. 
4. Once sample block has acclimatized, fix it onto the sample holder chuck using SCEM or 
OCT. Ensure sample block is positioned on chuck so that block edge is parallel to blade 
	 90 
edge. This may require some additional adjustments to get accurate positioning. Failing 
to do so can result in uneven, inconsistent sections. Allow freezing for 5 minutes.  
5. Secure the chuck with the sample block onto the holder. Ensure the bottom of the block 
edge is parallel with where the blade would sit. Adjust position of holder by turning the 
associated adjusting knob if necessary. 
6. Disengage the ratchet pawl handle located in the back of the cryostat chamber.  
7. Retract sample holder to starting position by pressing retract button on cryostat. This will 
move the system towards the back.  
8. Carefully place tungsten carbide blade in knife holder with forceps and secure.  
9. Adjust the position of the knife holder so that it is close to the sample with approximately 
1 mm of space between. Release the knife holder using its front lever and slide it 
backwards towards the block face edge. Secure knife holder in place. Use the advance 
button on the cryostat to slowly advance the blade forward, towards the sample. The 
sample should now be at a position that it can produce a thin section. It may take some 
adjustments to ensure the blade does not cut into the sample too deeply, which can 
damage the block or the specimen. 
10. Engage the ratchet pawl handle.  
11. Adjust the section thickness to 10-16 µm for trimming. To adjust section thickness, 
release the thickness knob and select the desired section thickness. Re-tighten the knob. 
12. Trim the block by rotating the handle located on the right side of the cryostat manually 
until the ROI appears on the cut surface. Clean away any cryoembedding medium or 
bone residue from the block surface and the blade every few sections using the paintbrush 
to keep sections clean and consistent. 
13. After trimming, move the blade edge to a new position or place a new, sharp blade into 
the knife holder. Set desired section thickness (~10 µm for rabbit tibiae).  
14. Remove the paper cover from the cryofilm by holding the metallic, non-sticky edge with 
forceps and peeling from the backing. Mount the cryofilm onto the clean, cut surface with 
the metallic section on the inferior edge of the ROI and tightly adhere the film to the 
block surface using the pre-chilled roller. 
15. Hold the edge of the cryotape with forceps as the section is cut such that the section does 
not fall off the stage during sectioning. Section the block in one quick, swift motion. The 
bone section should be stuck onto the cryofilm.  
16. Place the section tissue side up on a microscope slide within the cryostat. Allow sections 
to dry for 30 minutes. Then remove the slide from the cryostat and allow the cryo-
embedding medium to melt such that the section adheres to the surface of the slide. 
Sections can either be taped directly onto slides or mounted onto slides using 
fluorochrome protective mounting medium with a cover slip. Sections can be stored in 
slide boxes at -80°C.  
17. For analysis, assess fluorescent labels using a microscope with fluorescent capabilities. 
Images can be assembles into 3D volumetric renders for analysis.  
